
International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 76

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in *Cumulative List No. 16, 2015* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 76

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–113) et recommandées (1–74) dans la *Liste récapitulative No. 16, 2015* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 76

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–113) y Recomendadas (1–74) se encuentran reunidas en *Cumulative List No. 16, 2015* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

acebilustatum

acebilustat

4-[[[(1S,4S)-5-({4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl)methyl}-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl]benzoic acid


acébilustat

acide 4-[[[(1S,4S)-5-({4-[4-(1,3-oxazol-2-yl)phénoxy]phényl)méthyl}-2,5-diazabicyclo[2.2.1]heptan-2-yl)méthyl]benzoïque

acebilustat

ácido 4-[[[(1S,4S)-5-({4-[4-(1,3-oxazol-2-il)fenoxi]fenil)metil]-2,5-diazabicyclo[2.2.1]heptan-2-il]metil]benzoico

C₂₉H₂₇N₃O₄



alalevonadifloxacinum

alalevonadifloxacin

(5S)-8-[4-(L-alanyloxy)piperidin-1-yl]-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid


alalévonadifloxacine

acide (5S)-8-[4-(L-alanyloxy)pipéridin-1-yl]-9-fluoro-5-méthyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylique

alalevonadifloxacino

ácido (5S)-8-[4-(L-alaniloxi)piperidin-1-il]-9-fluoro-5-metil-1-oxo-6,7-dihidro-1H,5H-pirido[3,2,1-ij]quinolina-2-carboxílico

C₂₂H₂₆FN₃O₅



albusomatropinum # albusomatropin	human serum albumin (residues 1-585) fusion protein with human somatotropin (growth hormone) (residues 586-776), produced in yeast cells (<i>Saccharomyces cerevisiae</i>)
albusomatropine	albumine sérique humaine (résidus 1-585) protéine de fusion avec la somatotropine humaine (hormone de croissance) (résidus 586-776), produit par culture de levure (<i>Saccharomyces cerevisiae</i>)
albusomatropina	albúmina sérica humana (restos 1-585) proteína de fusión con la somatotropina humana (hormona de crecimiento) (restos 586-776), producida mediante cultivo de levadura (<i>Saccharomyces cerevisiae</i>)

Sequence/ Séquence / Secuencia

```

DAHKSEVAHR FRDLGGEENFK ALVLIIFAQY LQQCPFEDHV KLVNEVTEFA 50
KTCVADESAAE NCDKSLHTLF GDKLCTVATL RETYGMADCAKQEPERNE 100
CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKVKLY EIARRHPYFY 150
APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELDRDEG ASSAKQRLKC 200
ASLQKFGERA FKAWAVARLS QRFPAEFAE VSKLVTDLTK VHTECCGDDL 250
LECADDRADL AKYICENQDS ISSKLECEE KPLLEKSHCI AEVENDEMPA 300
DLPSLAADFV ESKDVCKNYA EAKDVFGLMF LYEYARRHPD YSVVLLRLA 350
KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 400
YKFQNALVLR YTKKVPQVST PTLVEVSRLN GKVSGKCKKH PEAKRMPCEA 450
DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK 500
EFNAETFTFH ADICTLSEKE RQIKKQTAHV ELVKHKPKAT KEQLKAVMDD 550
FAAFVEKCKC ADDKETCFAE EGKLLVAASQ AALGLFPPTIP LSRLFDNAML 600
RAHRLHQLAF DTYQEFEEAY IPKEQKYSFL QNPQTSLCFS ESIPFPSNRE 650
ETQQKSNLEL LRISLLLIQS WLEPVQFLRS VFANSLVYGA SDSNVYDLLK 700
DLEEGIQTLM GRLEDGSPRT GQIFKQTYSK FDTNSHNDDA LLKNYGLLYC 750
FRKDMDKVET FLRIVQCRSV EGS CGF 776

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

53-62 75-91 90-101 124-169 168-177 200-246 245-253
265-279 278-289 316-361 360-369 392-438 437-448 461-477
476-487 514-559 558-567 638-750 767-774

```

asunerceptum # asunercept	fusion protein for immune applications (FPIA) comprising the <i>Homo sapiens</i> FAS (Fas cell surface death receptor, TNFRSF6, tumor necrosis factor receptor (TNFR) superfamily member 6, FAS1, APO-1, CD95) extracellular domain, fused with <i>Homo sapiens</i> immunoglobulin G1 Fc fragment; <i>Homo sapiens</i> FAS precursor fragment 26-172 (1-147) - gamma1 chain H-CH2-CH3 fragment [<i>Homo sapiens</i> IGHG1*03 (hinge 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dimer (148-148':154-154':157-157')-trisdisulfide
asunercept	protéine de fusion pour applications immunitaires (FPIA) comprenant le domaine extracellulaire d' <i>Homo sapiens</i> FAS (récepteur de mort membranaire Fas, TNFRSF6, membre 6 de la superfamille des récepteurs du facteur de nécrose tumorale (TNFR), FAS1, APO-1, CD95), fusionné au fragment Fc de l'immunoglobuline G1 d' <i>Homo sapiens</i> ; <i>Homo sapiens</i> FAS fragment 26-172 du précurseur (1-147)-fragment H-CH2-CH3 de la chaîne gamma1 [<i>Homo sapiens</i> IGHG1*03 (charnière 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dimère (148-148':154-154':157-157')-trisdisulfure

asunercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende el dominio extracelular de *Homo sapiens* FAS (receptor de muerte Fas de membrana, TNFRSF6, miembro 6 de la superfamilia de receptores del factor de necrosis tumoral (TNFR), FAS1, APO-1, CD95), fusionado con el fragmento Fc de la inmunoglobulina G1 de *Homo sapiens*;

FAS de *Homo sapiens* fragmento 26-172 del precursor (1-147) -fragmento H-CH2-CH3 de la cadena gamma1 [*Homo sapiens* IGHG1*03 (bisagra 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dímero (148-148':154-154':157-157')-trisdisulfuro

Fused chain / chaîne fusionnée / cadena fusionada

```
QVTDINSKGL ELRKTVTVE TQNLEGLHHD QFCGHKPCPP GERKARDCTV 50
NGDEPDCVFC QEGKEYTDKA HFSSKRCRCR LCDEGHGLEV EINCRTQTNT 100
KCRCKNFNFC NSTVCEHCDP CTKCEHGIK ECTLTSNTKC KEEGSRCDK 150
THTCPFCFAP ELLGGPSVFL FPPKPKDTLM ISRTLPEVTCV VVDVSHEDPE 200
VKFNWYVDGV EVHNAKTKFR EEQYNSTYRV VSVLTVLHQD MINGKEYKCK 250
VSNKALPAPI EKTISKAKGQ PREPQVYTLF PSREEMTKNQ VSLTCLVKGK 300
YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFPLYSKLTV DKSRRWQQGNV 350
FSCVMHEAL HNHYTQKSL S LSPGK 375
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intrachain FAS	34-48	38-57	60-76	79-94
	82-102	104-118	121-132	124-140
	34'-48'	38'-57'	60'-76'	79'-94'
	82'-102'	104'-118'	121'-132'	124'-140'
IGHG1 (C23-C104)	189-249	295-353		
	189'-249'	295'-353'		

Interchain IGHG1 (h5, h 11, h 14) 148-148' 154-154' 157-157'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

FAS:
93, 111, 93', 111': complex mono-, bi-, tri- and tetra-antennary oligosaccharides, partially sialylated, oligosaccharides complexes de structure ramifiée (de 1 à 4 branches), partiellement sialylés, oligosacáridos complejos mono-bi, tri y tetra-antenido, parcialmente sialilados

IGHG1 CH2 N84.4:
225, 225': complex mono- and biantennary non-sialylated oligosaccharides, oligosaccharides complexes de structure ramifiée (de 1 à 2 branches) non-sialylés, oligosacáridos complejo mono- and biantenido non-sialilado

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales:

H CHS K2 C-terminal lysine clipping, coupure de la lysine C-terminale, supresión de lisina C-terminal: 375, 375'

avacopanum

avacopan

(2*R*,3*S*)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-*N*-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide


avacopan

(2*R*,3*S*)-2-[4-(cyclopentylamino)phényl]-1-(2-fluoro-6-méthylbenzoyl)-*N*-[4-méthyl-3-(trifluorométhyl)phényl]pipéridine-3-carboxamide

avacopán

(2*R*,3*S*)-2-[4-(ciclopentilamino)fenil]-1-(2-fluoro-6-metilbenzoil)-*N*-[4-metil-3-(trifluorometil)fenil]piperidina-3-carboxamida

C₃₃H₃₆F₄N₃O₂



bazilitoranum
bazilitoran

all-P-ambo-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-methyl-P-thioguanilyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-7-carba-2'-deoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-methyl-P-thioguanilyl-(3'→5')-2'-O-methyluridine

bazilitoran

tout-P-ambo-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-méthyl-P-thioguanilyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-7-carba-2'-déoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-méthyl-P-thioguanilyl-(3'→5')-2'-O-méthyluridine

bazilitorán

todo-P-ambo-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-7-carba-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metiluridina

C₁₇₉H₂₃₃N₅₂O₁₀₁P₁₇S₁₇

(3'→5')d(P-thio)(C-T-A-T-C-T-rGm-rUm-m5C-c7G-T-T-C-T-C-T-rGm-rUm)

Legend:

rGm = 2'-O-méthylguanosine

rUm = 2'-O-méthyluridine

m5C = 2'-deoxy-5-méthylecytidine

c7G = 2'-deoxy-7-carbaguanosine (C replaces N)

bevacizumabum beta #
bevacizumab beta

immunoglobulin G1-kappa, anti-[*Homo sapiens* VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized monoclonal antibody;

gamma1 heavy chain (1-453) [humanized VH (*Homo sapiens* IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (CH1 R120>K (220) (124-221), hinge (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (232-232":235-235")-bisdisulfide

bévacizumab bêta

immunoglobuline G1-kappa, anti-[*Homo sapiens* VEGFA (facteur de croissance A de l'endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-453) [VH humanisé (*Homo sapiens* IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (CH1 R120>K (220) (124-221), charnière (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (232-232":235-235")-bisdisulfure

bevacizumab beta

immunoglobulina G1-kappa, anti-[*Homo sapiens* VEGFA (factor de crecimiento A endotelial vascular, VEGF-A, VEGF)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-453) [VH humanizado (*Homo sapiens* IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (CH1 R120>K (220) (124-221), bisagra (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPFGSLRL SCAASGYTFT NYGMNWRQA PGKLEWVGV 50
INTYTGPEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYICAKYP 100
HYYGSSHWYF DVMGQGTLVV VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVRDYFPEPV TVSWNSGALT SGVHTFFPAVL QSSGLYLSLS VVTVPSSSLG 200
TQTYICNWNH KPSNTKVDK VEPKSCDRTH TCPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPVETCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKQQR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFPY SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSMVHEALHN HYTKSKLSLS 450
PGK 453
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRTV ITCSAQDIS NYLNWYQQKPK GKAPKVLIIYF 50
TSSLHSGVPS RFGSGSGSDT FTLTISLQPF EDFATYYCQQ YSTVPWTFGG 100
GTRKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYKHKH YVACEVTHGQ 200
LSSPVTKSPN RGEK 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H (C23-C104) 22-96 150-206 267-327 373-431
22"-96" 150"-206" 267"-327" 373"-431"
Intra-L (C23-C104) 23"-88" 134'-194"
23"-88" 134"-194"
Inter-H-L (h 5-CL 126) 226-214' 226"-214"
Inter-H-H (h 11, h 14) 232-232" 235-235"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84,4;
303, 303"
Fucosylated complex bi-antennary CHO-type glycans, with a level of galactosylated A2G2F > 1.5% and of high mannose Man5 > 0.9% / glycanes de type CHO bi-antennaires complexes fucosylés, avec un taux de galactosylé A2G2F > 1.5% et de riche en mannose Man5 > 0.9% / glicanos de tipo CHO biantenararios complejos fucosilados, con una tasa de galactosilado A2G2F > 1.5% y de alta manosa Man5 > 0.9%

blontuvmabum #
blontuvmab

immunoglobulin G2_V-kappa-C-lambda, anti-[*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], caninized monoclonal antibody;
gamma2 heavy chain chimeric (1-448) [*Mus musculus* VH (*Mus musculus* IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -*Canis lupus familiaris* IGHG2*02 (CH1 T26>Q (131) (114-211), hinge (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfide with V-kappa-C-lambda light chain chimeric (1'-219') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -*Canis lupus familiaris* IGL1CS1*01 V45.3>I (162) (114'-219')]; dimer (225-225'':228-228'')-bisdisulfide

blontuvmab

immunoglobuline G2_V-kappa-C-lambda, anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal caninisé;
chaîne lourde gamma2 chimérique (1-448) [*Mus musculus* VH (*Mus musculus* IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -*Canis lupus familiaris* IGHG2*02 (CH1 T26>Q (131) (114-211), charnière (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfure avec la chaîne légère V-kappa-C-lambda chimérique (1'-219') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -*Canis lupus familiaris* IGL1CS1*01 V45.3>I (162) (114'-219')]; dimère (225-225'':228-228'')-bisdisulfure

blontuvmab

inmunoglobulina G2_V-kappa-C-lambda, anti-[*Homo sapiens* MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal caninizado;
cadena pesada gamma2 quimérica (1-448) [*Mus musculus* VH (*Mus musculus* IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -*Canis lupus familiaris* IGHG2*02 (CH1 T26>Q (131) (114-211), bisagra (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfuro con la cadena ligera V-kappa-C-lambda quimérica (1'-219') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -*Canis lupus familiaris* IGL1CS1*01 V45.3>I (162) (114'-219')]; dímero (225-225'':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLQQSRAE LVRPGASVTL SCKPSSGYTFT DYEYVHWVKQT PVHGLEWIGA 50
 IDPETGGTAD NQKFKGKAIL TADKSSSTAY MELRSLTSED SAVYYCTNFV 100
 DVWGTGTTVT VSSASTTAPS VFPLAPSCGS QSGSTVALAC LVSGYFPEPV 150
 TVSWNSGSLT SGVHTFFSVL QSSGLYSLSS MVTVPSSRWP SETFTCNVAH 200
 PASKTKVKDP VPKRENGRVP RPPDCPKCPA FEMLGGPSVF IFPPKPKDTL 250
 LIARTFEVTC VVVDLDFEDP EVQISWFDG KQMQTAKTQP REEQFNQTYR 300
 VVSVLPIGHQ DWLKGKQFTC KVNKALPSP IERTISKARG QAHQPSVYVL 350
 PPSREELSKN TVSLTCLIKD FFFPDIDVEW QSNQQEPEP KYRTPFPQLD 400
 EDGSYFLYSK LSVDKSRWQR GDTFICAVMH EALHNYTQK SLSHSPGK 448

Light chain / Chaîne légère / Cadena ligera
 DVVMSQSPSS LAVSVGEKVT MSCKSSQSLL YSGNQKNYLA WYQQKPGQSP 50
 RLLIYWASTR ESGVPDRFTG SSGTDFTLT ISSVKAEDLA VFYCCQYYNY 100
 PLTFGGGTHL TVLQPKASP SVTLFPSSSE ELGANKATLV CLISDFYPSG 150
 VTVAMKADGS PITQGVETK PSKQSNKYA ASSYLSLTPD KWKSHSFPSC 200
 LVTHEGSTVE KKVAPAEC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 140-196 260-320 366-426
 22"-96" 140"-196" 260"-320" 366"-426"
 Intra-L (C23-C104) 23"-94" 141"-200
 23"-94" 141"-200"
 Inter-H-L (CHI 11-CL 126) 128-218" 128"-218"
 Inter-H-H (h 14, h 17) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 296, 296"

brimapidum
brimapidide

D-α-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl-D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl-D-asparaginyl-D-leucyl-D-threonyl-D-threonyl-D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide

brimapidide

D-α-aspartyl-D-glutaminyl-D-séryl-D-arginyl-D-prolyl-D-valyl-D-glutaminyl-D-prolyl-D-phénylalanil-D-leucyl-D-asparaginyl-D-leucyl-D-thréonyl-D-thréonyl-D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide

brimapidida

D-α-aspartil-D-glutaminil-D-seril-D-arginil-D-prolil-D-valil-D-glutaminil-D-prolil-D-fenilalanil-D-leucil-D-asparaginil-D-leucil-D-treonil-D-treonil-D-prolil-D-arginil-D-lisil-D-prolil-D-arginil-D-prolil-D-prolil-D-arginil-D-arginil-D-arginil-D-glutaminil-D-arginil-D-arginil-D-lisil-D-lisil-D-arginilglicinamida



D-Aminoacids sequence / Séquence des D-aminoacides /
 Secuencia de D-aminoácidos

DQSRPVQPFL NLTPRKPRP PRRRQRRKKR G 31

Modified residue / Résidu modifié / Resto modificado

G = glycinamide

cabiralizumabum #

cabiralizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* CSF1R (colony stimulating factor 1 receptor, CSF-1R, CSF-1-R, macrophage colony-stimulating factor 1 receptor, c-fms, FMS, CD115)], humanized monoclonal antibody; gamma4 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), hinge S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') - *Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (228-228":231-231")-bisdisulfide

cabiralizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* CSF1R (récepteur du facteur 1 stimulant de colonies, CSF-1R, CSF-1-R, récepteur du facteur 1 stimulant des colonies de macrophages, c-fms, FMS, CD115)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-449) [VH humanisé (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), charnière S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') - *Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (228-228":231-231")-bisdisulfure

cabiralizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* CSF1R (receptor del factor 1 de estimulación de colonias, CSF-1R, CSF-1-R, receptor del factor 1 de estimulación de colonias de macrófagos, c-fms, FMS, CD115)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-449) [VH humanizado (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), bisagra S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') - *Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWMGD 50
 INPYNIGGTF NQKFKGRVTI TADKSTSTAY MELSSLRSED TAVVYCARES 100
 PYFSNLYVMD YWQQTLLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
 VKDYFPEFVT VSNWNGALTS GVHTFFAVLQ SSGLYSLSSV VTFVSSSLGT 200
 KTYTCNVDHK PSNTKVDKRV ESKYGPCCPP CPAPEFLGGP SVFLFPKPK 250
 DTLMISRTP E VTCVVVDVSO EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
 TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIERKISK AKGQPREPQV 350
 YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPEVL 400
 DSDGSSFLYS RLTVDKSRWQ EGNVFCSSVM HEALHNHYTQ KSLSLSLGK 449

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT LSLSPGERAT LSCKASQSV DGDNYMNYWY QOKFGQAPRL 50
 LIYAASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCHLSNEDLS 100
 TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
 QWKVDNALQS GNSQESVTEQ DSKDSTYSL S TLTLSKADY EKHKVYACEV 200
 THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 263-323 369-427
 22'-96" 149'-205" 263'-323" 369'-427"
 Intra-L (C23-C104) 23-92 138'-198"
 23"-92" 138"-198"
 Inter-H-L (CH1 10-CL 126) 136-218 136'-218"
 Inter-H-H (h 8, h 11) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

carotuximabum #
 carotuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* ENG (endoglin, Osler-Rendu-Weber syndrome 1, ORW1, ORW, HHT1, CD105)], chimeric monoclonal antibody; gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfide with kappa light chain (1'-213')] [chimeric V-KAPPA (*Mus musculus* IGKV4-72*01 -*Homo sapiens* IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimer (227-227":230-230")-bisdisulfide

carotuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* ENG (endogline, syndrome 1 d'Osler-Rendu-Weber, ORW1, ORW, HHT1, CD105)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfure avec la chaîne légère kappa (1'-213')] [V-KAPPA chimérique (*Mus musculus* IGKV4-72*01 -*Homo sapiens* IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimère (227-227":230-230")-bisdisulfure

carotuximab

immunoglobulina G1-kappa, anti-[*Homo sapiens* ENG (endoglina, síndrome 1 de Osler-Rendu-Weber, ORW1, ORW, HHT1, CD105)], anticuerpo monoclonal quimérico;

cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA quimérico (*Mus musculus* IGKV4-72*01 -*Homo sapiens* IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dímero (227-227":230-230")-bisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVKLEESGGG LVQPGGSMKL SCAASGFTFS DAWMDWVRQS PEKGLEWVAE 50
 IRKASNHAT YYAESVKGRF TISRDDSKSS VYLQMNLSRA EDTGIYYCTR 100
 WRRFFDSWGQ GTTLTVSSAS TKGPSVFLA PSSKSTSGGT AALGCLVKDY 150
 FPEPVTVSWN SGALTSVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
 CNVNHKFSNT KVDKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPKPKD 250
 TLMISRTPEV TCVVVDVSHS DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
 TLPSPRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQFEN NYKTTFPVLD 400
 SDGSFFLYSK LTVDKSRWQQ GNVFSCSMVMH EALHNHYTQK SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligera

QIVLSQSPAI LSASPGEKVT MTRCASSVS YMHWYQQKPG SSPKPWIYAT 50
 SNLASGVVPR FSGSGSSTSY SLTISRVEAE DAATYYCQW SSNFLITFGAG 100
 TKLELKRIVA APSVFI FPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
 NALQSGNSQE SVTEQDSKDS TYSLSTLTL SKADYKHKV YACEVTHQGL 200
 SSPVTKSFNR GEC 213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-98	145-201	262-322	368-426
	22"-98"	145"-201"	262"-322"	368"-426"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23"-87"	133"-193"		
Inter-H-L (h 5-CL 126)	221-213'	221"-213"		
Inter-H-H (h 11, h 14)	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

cefiderocolum

cefiderocol


(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-1,3-thiazol-4-yl)-2-[[2-(2-carboxipropan-2-yl)oxy]imino]acetamido]-3-{{1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidin-1-ium-1-yl)methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

céfidéocol

(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-1,3-thiazol-4-yl)-2-[[2-(2-carboxipropan-2-yl)oxy]imino]acétamido]-3-{{1-[2-(2-chloro-3,4-dihydroxybenzamido)éthyl]pyrrolidin-1-ium-1-yl)méthyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate

cefiderocol

(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-1,3-thiazol-4-il)-2-[[2-(2-carboxipropan-2-il)oxi]imino]acetamido]-3-{{1-[2-(2-cloro-3,4-dihidroxi benzamido)etil]pirrolidin-1-ium-1-il}metil)-8-oxo-5-tia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxilato





cemisiranum
cemisiran

duplex of [(2*S*,4*R*)-1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({(3-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido)propyl)amino]-3-oxopropoxy)methyl]-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl]-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all-P-ambo*-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-deoxy-2'-fluoroguanlyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanlyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyl-3'-adenylate and *all-P-ambo*-thymidylyl-(5'→3')-thymidylyl-(5'→3')-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroguanlyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-*O*-methyluridine

cemisiran

duplex de l'hydrogène-*tout-P-ambo*-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-déoxy-2'-fluoroguanlyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanlyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyl-3'-adénylate de





Legend

X: 2'-deoxyx-2'-fluoro

X: 2'-O-methyl

Z: thymidine



clivatuzumabum tetraxetanum #
 clivatuzumab tetraxetan

immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 (mucin 1, polymorphic epithelial mucin, PEM, CD227)], humanized monoclonal antibody, tetraxetan conjugate; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*03, G1m3 (CH1 (120-217), (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer; tetraxetan (DOTA) conjugate (on an average of 4 to 7 lysyl, linked to the chelator by their N^ε)

clivatuzumab tétraxétan

immunoglobuline G1-kappa, anti-[*Homo sapiens* MUC1 (mucine 1, mucine épithéliale polymorphique, PEM, CD227)], anticorps monoclonal humanisé, conjugué au tétraxétan; chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*03, G1m3 (CH1 (120-217), (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure; conjugué au tétraxétan (DOTA) (avec une moyenne de 4 à 7 lysyl liés au chélateur par leur N^ε)

clivatuzumab tetraxetán

immunoglobulina G1-kappa, anti-[*Homo sapiens* MUC1 (mucina 1, mucina epitelial polimórfica, PEM, CD227)], anticuerpo monoclonal humanizado, conjugado con tetraxetán;

cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*03, G1m3 (CH1 (120-217), (bisagra 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizado (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dímero (228-228":231-231")-bisdisulfuro; conjugado con tetraxetán (DOTA) (con una media de 4 a 7 restos lisil unidos al quelante por sus respectivos N⁶)

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLQQSGAE VKKPGASVKV SCEASGYTFP SYVLHWVKQA PGQGLEWIGY 50
INPNDGTQY NEKFKGKATL TRDTSINTAY MELSLRLSDD TAVYYCARGF 100
GGSYGFAYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSQVH TFPVAVLQSSG LYSLSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVPEK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMI SRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK ARGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFCSSVM HEALHNHYTQ KLSLSLSPGK 449

```

Light chain / Chaîne légère / Cadena ligera

```

DIQLTQSPSS LSASVGRVIT MTCASSSVS SSYLYWYQQK PGKAPKLWIY 50
STSNLASGVP ARFSGSGSGT DFTLTISSQL PEDSASYFCH QWNRYPYTFG 100
GGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSLSTL TSKADYEKH KVVACEVTHQ 200
GLSSPVTKSF NRGEC 215

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
                22"-96" 146"-202" 263"-323" 369"-427"
Intra-L (C23-C104) 23"-89" 135"-195"
                23"-89" 135"-195"
Inter-H-L (h 5-CL 126) 222-215' 222"-215"
Inter-H-H (h 11, h 14) 228-228" 231-231"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación


H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

Modified residues / Résidus modifiés / Restos modificados

4 to 7 lysyl (K)
4 à 7 lysyl (K)
4 a 7 lisil (K)

N⁶-(tetraxetan)-L-lysyl

crotedumabum #
crotedumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* GCGR (glucagon receptor)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-455) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-128) - IGHG4*01 (CH1 (129-226), hinge S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-455)], (142-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-17*01 (95.80%) - IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimer (234-234":237-237")-bisdisulfide

crotédumab immunoglobuline G4-kappa, anti-[*Homo sapiens* GCGR (récepteur du glucagon)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-455) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01 [8.8.21] (1-128) -IGHG4*01 (CH1 (129-226), charnière S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-455)], (142-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ3*01 [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimère (234-234":237-237")-bisdisulfure

crotedumab inmunoglobulina G4-kappa, anti-[*Homo sapiens* GCGR (receptor de glucagón)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma4 (1-455) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01 [8.8.21] (1-128) -IGHG4*01 (CH1 (129-226), bisagra S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-455)], (142-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ3*01 [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dímero (234-234":237-237")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYLMNWVRQA PGKGLEWLAN 50
IQEDGIEKYY VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREP 100
SHYDILTGYD YYYGMDVWGQ GTTVTVSSAS TKGPSVFFLA PCSRSTSEST 150
AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP 200
SSSLGKTYT CNVDHKFSNT KVDKRVESKY GPPCFPCFAP EFLGGPVSFL 250
FPPKPKDTLM ISRTPEVTCV VVDVVSQEDPE VQFNWYVDGV EVHNAKTKPR 300
EEQFNSTYRV VSVLTVLHQD WLNGKEYKCF VSNKGLPSSI EKTISKAKGQ 350
PREPQVYTLF PSQEEETKQK VSLTCLYKCF YPSDIAVEWE SNGQPENNYK 400
TTPPVLSDG SFFLYSRLTV DKSRWQEGNV FSCSVMEAL HNHYTQKSL 450
LSLGK 455



Light chain / Chaîne légère / Cadena ligera
DIQMTQSPSS LSASVGRVIT ITCRASQGITR NDLGWYQQKPK GKAPKRLIYA 50
ASSLQSGVPS RFGSGSGSTE FILTVSSLQF EDFATYYCLO YNSNPFTEPG 100
GTVVDIKRTV AAPSVEFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQMKV 150
DNALQSGNSQ ESVTEQDSKDT STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGECC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 155-211 269-329 375-433
22"-96" 155"-211" 269"-329" 375"-433"
Intra-L (C23-C104) 23"-88" 134"-194"
23"-88" 134"-194"
Inter-H-L (CH1 10-CL 126) 142-214" 142"-214"
Inter-H-H (h 8, h 11) 234-234" 237-237"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
305, 305"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

dapansutrilum
dapansutrilum 3-(methanesulfonyl)propanenitrile
dapansutrilum 3-(méthanesulfonyl)propanenitrile
dapansutrilum 3-(metanosulfonyl)propanonitrilo

**deudextromethorphanum**



deudextromethorphan

3-[(²H₃)methoxy]-17-[(²H₃)methyl]-*ent*-morphinan

deudextromethorpane

3-[(²H₃)méthoxy]-17-[(²H₃)méthyl]-*ent*-morphinane

deudextrometorfanò

3-[(²H₃)metoxi]-17-[(²H₃)metil]-*ent*-morfinano**dociparstatum natricum**

dociparstat sodium


sodium salt of 2,3-di-O-desulfoheparin, the starting material is an unfractionated heparin from porcine intestinal mucosa, the relative average molecular mass is approximately 12,000 daltons with about 40% ranging between 8,000 and 16,000 daltons, the degree of sulfation is about 2.0 per disaccharidic unit

dociparstat sodique

sel de sodium de la 2,3-di-O-désulfohéparine, obtenu à partir d'héparine non-fractionnée de la muqueuse intestinale porcine; sa masse moléculaire relative dont environ 40% est comprise entre 8.000 et 16.000 daltons, est voisine de 12.000 daltons; son degré de sulfatation est d'environ 2,0 par unité disaccharide

dociparstat sodico

sal de sodio de la 2,3-di-O-desulfoheparina, obtenida a partir de la heparina no fraccionad de la mucosa intestinal porcina; la masa molecular relativa media es aproximadamente de 12000 daltons con el 40% comprendido entre 8000 y 16000 daltons; el grado de sulfatación es de 2,0 por unidad de disacárido.





dolcanatidum

dolcanatide 1D, 16D-[3-L-glutamic acid]human uroguanylin:
S⁴, S¹²:S⁷, S¹⁵-dicyclo(D-asparaginyL-L-α-aspartyl-L-α-glutamyl-L-cysteinyl-L-α-glut-amyL-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyL-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-D-leucine)

dolcanatide 1D, 16D-[3-acide L-glutamique]uroguanyline humaine:
S⁴, S¹²:S⁷, S¹⁵-dicyclo(D-asparaginyL-L-α-aspartyl-L-α-glutamyl-L-cystéinyl-L-α-glut-amyL-L-leucyl-L-cystéinyl-L-valyl-L-asparaginyL-L-valyl-L-alanyl-L-cystéinyl-L-thréonylglycyl-L-cystéinyl-D-leucine)

dolcanatida 1D, 16D-[3-L-ácido glutámico]uroguanilina humana:
S⁴, S¹²:S⁷, S¹⁵-díciclo(D-asparaginyL-L-α-aspartil-L-α-glutamyl-L-cisteinil-L-α-glut-amil-L-leucil-L-cisteinil-L-valil-L-asparaginyL-L-valil-L-alanyl-L-cisteinil-L-treonilglicil-L-cisteinil-D-leucina)



domagrozumabum #

domagrozumab immunoglobulin G1-kappa, anti-[*Homo sapiens* MSTN (growth differentiation factor 8, GDF8, myostatin,GDF-8)], humanized monoclonal antibody; gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens*IGHV3-23*03 (94.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116)-IGHG1*01 (CH1 (117-214), hinge (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-bisdisulfide

domagrozumab immunoglobuline G1-kappa, anti-[*Homo sapiens* MSTN (facteur de croissance et de différenciation 8, GDF8, myostatine, GDF-8)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens*IGHV3-23*03 (94.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116)-IGHG1*01, G1m17,1 (CH1 (117-214), charnière (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')- disulfure avec la chaîne légère (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228")-bisdisulfure

domagrozumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MSTN (factor de crecimiento y de diferenciación 8, GDF8, miostatina, GDF-8)], anticuerpo monoclonal humanizado; cadena pesada gamma 1 (1-446) [VH humanizado (*Homo sapiens*IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01 (CH1 (117-214), bisagra (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01, Km3 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESQGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVST 50
ISSGGSYTSY PDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQD 100
YAMNYWGQGT LVTSSASTK GPSVFLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTVSGVHTFP AVLQSSGLYS LSSVTVVPSL SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KHTTCPPCPA PEAAGAPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTSKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRTV ITCKASQDVS TAVAWYQQKP GKAPKLLIYS 50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYICQQ HYSTPWFVFG 100
GTKVEIKRTP AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSLTIT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 260-320 366-424
 22"-96" 143"-199" 260"-320" 366"-424"
 Intra-L (C23-C104) 23-88" 134-194"
 23"-88" 134"-194"
 Inter-H-L (h 5-CL 126) 219-214' 219"-214"
 Inter-H-H (h 11, h 14) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 296, 296"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
 Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
 C-terminal trimming of the C-terminal lysine (K)
 H CHS K2:
 446, 446"

edasonexentum

edasonexent


N-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaenamido]ethyl}-2-hydroxybenzamide

édasonexent

N-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaénamido]éthyl}-2-hydroxybenzamide

edasonexento

N-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaenamido]etil}-2-hidroxibenzamida

C₂₈H₃₉N₃O₂

edonerpicum

edonerpic


1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidín-3-ol

édonerpic

1-{3-[2-(1-benzothiophén-5-yl)éthoxy]propyl}azétidín-3-ol

edonerpico

1-{3-[2-(1-benzotiofen-5-il)etoxi]propil}azetidín-3-ol

C₁₆H₂₁NO₂S**enoblituzumabum #**

enoblituzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], humanized monoclonal antibody; gamma1 heavy chain (1-452) [humanized VH (*Homo sapiens* IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (CH1 (123-220), hinge (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa light chain (1'-214')] [humanized V-KAPPA (*Homo sapiens* IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (231-231":234-234")-bisdisulfide

énoblituzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-452) [VH humanisé (*Homo sapiens* IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (CH1 (123-220), charnière (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214')] [V-KAPPA humanisé (*Homo sapiens* IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (231-231":234-234")-bisdisulfure

enoblituzumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-452) [VH humanizado (*Homo sapiens* IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (CH1 (123-220), bisagra (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214')] [V-KAPPA humanizado (*Homo sapiens* IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVELVESGGG LVQPGGSLRL SCAASGFTFT SYWMSWVRQA PGKGLELVSS 50
 ITSYGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARNM 100
 YTHFDSWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVVPS SSLGTQTYIC 200
 NVNHHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTIKAK GQPREPQVYT 350
 LPFSDDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPPVLD 400
 DGSFFLYSKL TVDKSRWQQG NVFSCSVMH EALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligera

DIVLTQPPSV SGAPGQRVTI SCSGSSSNI G SNSVSYQQ L PGTAPKLLIY 50
 DNSKRPSGVP DRFSGSKSGT SASLAITGLQ SEDEADYCYQ SRDTYGYVWV 100
 FGGGKLTVL GQPKAAPSVT LFPSSSEELQ ANKATLVCLI SDFYPGAVTV 150
 AWKGDSSPVK AGVETTPSK QSNKYYAASS YLSLTPEQWK SHRSYSCQVT 200
 HEGSTVEKTV APTECS 216

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	261-321	367-425
	22"-96"	144"-200"	261"-321"	367"-425"
Intra-L (C23-C104)	22-89	138-197		
	22"-89"	138"-197"		
Inter-H-L (h 5-CL 126)	220-215'	220"-215"		
Inter-H-H (h 11, h 14)	226-226'	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

297, 297"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

epacadostatum

epacadostat


(Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-3-carboximidamide

épacadostat

(Z)-N-(3-bromo-4-fluorophényl)-N'-hydroxy-4-[[2-(sulfamoylamino)éthyl]amino]-1,2,5-oxadiazole-3-carboximidamide

epacadostat

(Z)-N-(3-bromo-4-fluorofenil)-N'-hidroxi-4-[[2-(sulfamoylamino)etil]amino]-1,2,5-oxadiazol-3-carboximidamida

C₁₁H₁₃BrFN₇O₄S**esaxerenonum**

esaxerenone


(5P)-1-(2-hydroxyethyl)-N-[4-(methanesulfonyl)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide

ésaxérénone

(5P)-1-(2-hydroxyéthyl)-N-[4-(méthanesulfonyl)phényl]-4-méthyl-5-[2-(trifluorométhyl)phényl]-1H-pyrrole-3-carboxamide

esaxerenona

(5P)-1-(2-hidroxietil)-N-[4-(metanosulfonyl)fenil]-4-metil-5-[2-(trifluorometil)fenil]-1H-pirrol-3-carboxamida

C₂₂H₂₁F₃N₂O₄S**fexapodidum**

fexapotide



L-isoleucyl-L- α -aspartyl-L-glutaminy-L-glutaminy-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L- α -glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-L-leucine

fexapotide

L-isoleucyl-L- α -aspartyl-L-glutaminy-L-glutaminy-L-valyl-L-leucyl-L-séryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L- α -glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cystéinyl-L-leucine

fexapotida



L-isoleucil-L- α -aspartil-L-glutaminil-L-glutaminil-L-valil-L-leucil-L-seril-L-arginil-L-isoleucil-L-lisil-L-leucil-L- α -glutamil-L-isoleucil-L-lisil-L-arginil-L-cisteinil-L-leucina

C₉₀H₁₆₃N₂₇O₂₅S**flortaucipirum (¹⁸F)**flortaucipir (¹⁸F)7-[6-(¹⁸F)fluoropyridin-3-yl]-5H-pyrido[4,3-b]indoleflortaucipir (¹⁸F)7-[6-(¹⁸F)fluoropyridin-3-yl]-5H-pyrido[4,3-b]indoleflortaucipir (¹⁸F)7-[6-(¹⁸F)fluoropiridin-3-il]-5H-pirido[4,3-b]indolC₁₆H₁₀¹⁸FN₃**fonadelparum**

fonadelpar

{[5-methyl-3-(2-{4-(propan-2-yl)-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}ethyl)-1,2-benzoxazol-6-yl]oxy}acetic acid

fonadelpar	acide {[5-méthyl-3-(2-{4-(propan-2-yl)-2-[4-(trifluorométhyl)phényl]-1,3-thiazol-5-yl}éthyl)-1,2-benzoxazol-6-yl]oxy}acétique
fonadelpar	ácido {[5-metil-3-(2-{4-(propan-2-il)-2-[4-(trifluorometil)fenil]-1,3-tiazol-5-il}etil)-1,2-benzoxazol-6-il]oxi}acético



galcanezumabum #
galcanezumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* CALCA (calcitonin-related polypeptide alpha, calcitonin 1, CALC1) and *Homo sapiens* CALCB (calcitonin-related polypeptide beta, calcitonin 2, CALC2)], humanized monoclonal antibody;
gamma4 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), hinge S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-bisdisulfide

galcanézumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* CALCA (polypeptide alpha apparenté à la calcitonine, calcitonine 1, CALC1) et *Homo sapiens* CALCB (polypeptide beta apparenté à la calcitonine, calcitonine 2, CALC2)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-445) [VH humanisé (*Homo sapiens* IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), charnière S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228") bisdisulfure

galcanezumab

immunoglobulina G4-kappa, anti-[*Homo sapiens* CALCA (polipéptido alfa relacionado con la calcitonina, calcitonina 1, CALC1) y *Homo sapiens* CALCB (polipéptido beta relacionado con la calcitonina, calcitonina 2, CALC2)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-445) [VH humanizado (*Homo sapiens* IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01 [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), bisagra S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGSSVKV SKKASGYTFG NYWMQWRQA PGQGLEWMGA 50
IYEGTGKTVY IQKFADRVTI TADKSTSTAY MELSSLRSED TAVYYCARLS 100
DYVSGFGYWG QGTFVTVSSA STKGFSTVPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAPLQSSG LYSLSSTVTV PSSSLGKTLY 200
TCNVDHKPSN TKVDKRVESK YGPPCPCPA PEAAGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVQEDP EVQFNWYVDG VEVHNAKTKF REEQLFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTIKSKAG QPREPQVYTL 350
PFSQEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTFPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LNHHTYQKSL SLSLG 445

```

Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPSS LSASVGRVIT ITCRAKDIS KYLNWYQQKFP GKAPKLLIYY 50
TSGYHSGVPS RFGSGSGTD FTLTISSLPQ EDFATYYCQQ GDALPPTFGG 100
GTRKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEN 214

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22'-96" 146'-202" 260'-320" 366'-424"
 22"-96" 146"-202" 260"-320" 366"-424"
 Intra-L (C23-C104) 23'-88" 134'-194"
 23"-88" 134"-194"
 Inter-H-L (CH1 10-CL 126) 133'-214" 133"-214"
 Inter-H-H (h 8, h 11) 225'-225" 228'-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 296, 296"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaricos complejos fucosilados

galidesivirum

galidesivir

(2*S*,3*S*,4*R*,5*R*)-2-(4-amino-5*H*-pyrrolo[3,2-*d*]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol


galidésivir

(2*S*,3*S*,4*R*,5*R*)-2-(4-amino-5*H*-pyrrolo[3,2-*d*]pyrimidin-7-yl)-5-(hydroxyméthyl)pyrrolidine-3,4-diol

galidesivir

(2*S*,3*S*,4*R*,5*R*)-2-(4-amino-5*H*-pirrolo[3,2-*d*]pirimidin-7-il)-5-(hidroximetil)pirrolidina-3,4-diol

C₁₁H₁₅N₅O₃



givosiranum

givosiran

duplex of [(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)methyl}-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl)-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all-P-ambo*-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanlylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanlylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroguanlylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyl-3'-adenylate and *all-P-ambo*-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-*O*-methyl-*P*-thioguanlylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroguanlylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-*O*-methyluridine



givosiran

duplex de l'hydrogène-*tout-P-ambo*-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanlylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanlylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroguanlylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyl-3'-adénylate de [(2*S*,4*R*)-1-{1-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)méthyl}-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl)-4-hydroxypyrrolidin-2-yl]méthyle et

du *tout-P-ambo-2'-O-méthyl-P-thiouridylyl-(5'→3')-2'-O-méthyl-P-thioguanilyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylcytidilyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylcytidilyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylcytidilyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylcytidilyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroguanilyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thioadénylyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thioadénylyl-(5'→3')-2'-O-méthyluridine*

givosirán



dúplex del hidrógeno-*todo-P-ambo-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metil-3'-adenilato de [(2*S*,4*R*)-1- $\{1-[(2$ -acetamido-2-desoxi- β -D-galactopiranosil)oxil]-16,16-bis({3-[3-{5-[(2-acetamido-2-desoxi- β -D-galactopiranosil)oxil]pentanamido)propil}amino]-3-oxopropoxi)metil)-5,11,18-trioxo-14-oxa-6,10,17-triazanacosan-29-olil}-4-hidroxipirrolidin-2-il]metilo y del *todo-P-ambo-2'-O-metil-P-tiouridilil-(5'→3')-2'-O-metil-P-tioguanilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(5'→3')-2'-O-metiluridina**



Legend

X : 2'-deoxy-2'-fluoro

X : 2'-O-methyl



glecaprevirum

glecaprevir


(3*aR*,7*S*,10*S*,12*R*,21*E*,24*aR*)-7-*tert*-butyl-*N*-{(1*R*,2*R*)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-2,3,3*a*,5,6,7,8,11,12,20,23,24*a*-dodecahydro-1*H*,10*H*-9,12-methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-*b*]quinoxaline-10-carboxamide

glécaprévir

(3*aR*,7*S*,10*S*,12*R*,21*E*,24*aR*)-7-*tert*-butyl-*N*-{(1*R*,2*R*)-2-(difluorométhyl)-1-[(1-méthylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-2,3,3*a*,5,6,7,8,11,12,20,23,24*a*-dodécahydro-1*H*,10*H*-9,12-méthanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadécino[11,12-*b*]quinoxaline-10-carboxamide

glecaprevir

(3*aR*,7*S*,10*S*,12*R*,21*E*,24*aR*)-7-*tert*-butil-*N*-{(1*R*,2*R*)-2-(difluorometil)-1-[(1-metilciclopropano-1-sulfonyl)carbamoi]ciclopropil}-20,20-difluoro-5,8-dioxo-2,3,3*a*,5,6,7,8,11,12,20,23,24*a*-dodecahidro-1*H*,10*H*-9,12-metanociclopenta[18,19][1,10,17,3,6]trioxadiazaciclonoñadecino[11,12-*b*]quinoxalina-10-carboxamida

C₃₈H₄₆F₄N₆O₉S**glesatinibum**

glesatinib



N-[(3-fluoro-4-[[2-(5-[(2-methoxyethyl)amino]methyl)pyridin-2-yl]thieno[3,2-*b*]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-(4-fluorophenyl)acetamide

glésatinib

N-[(3-fluoro-4-[[2-(5-[(2-méthoxyéthyl)amino]méthyl)pyridin-2-yl]thiéno[3,2-*b*]pyridin-7-yl]oxy}phényl)carbamothioyl]-2-(4-fluorophényl)acétamide

glesatinib

N-[(3-fluoro-4-[[2-(5-[(2-metoxietil)amino]metil]piridin-2-il)tieno[3,2-*b*]piridin-7-il]oxi]fenil)carbamotioil]-2-(4-fluorofenil)acetamida




inclisiranum
inclisiran

duplex of [(2*S*,4*R*)-1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)methyl}-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl)-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all-P-ambo*-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroguanlylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-thymidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyl-3'-uridylyl and *all-P-ambo*-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroguanlylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiocytidylyl-(5'→3')-2'-*O*-methyladenosine

inclisiran

duplex de l'hydrogéno-*tout-P-ambo*-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroguanlylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-thymidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyl-3'-uridylyl de





Legend

X : 2'-deoxy-2'-fluoro

X : 2'-O-methyl

T : thymidine



intepirdinum

intepirdine



3-(benzenesulfonyl)-8-(piperazin-1-yl)quinolone

intépidine

3-(benzènesulfonyl)-8-(pipérazin-1-yl)quinolone

intepirdina

3-(bencenosulfonyl)-8-(piperazin-1-il)quinolina



ivosidenibum

ivosidenib


(2S)-N-((1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide

ivosidénib

(2S)-N-((1S)-1-(2-clorofenil)-2-[(3,3-difluorociclobutil)amino]-2-oxoetil)-1-(4-cianopiridin-2-yl)-N-(5-fluoropiridin-3-yl)-5-oxopirrolidina-2-carboxamida

ivosidenib

(2S)-N-((1S)-1-(2-clorofenil)-2-[(3,3-difluorociclobutil)amino]-2-oxoetil)-1-(4-cianopiridin-2-il)-N-(5-fluoropiridin-3-il)-5-oxopirrolidina-2-carboxamida



lanadelumabum #

lanadelumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* KLKB1 (kallikrein B 1, plasma prekallikrein (zymogen), kininogenin, Fletcher factor) proteolytically cleaved by F12 (factor FXII), active plasma kallikrein (EC 3.4.21.34)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -IGHG1*03, G1m3 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451))(123-451)], (225-213')-disulfide with kappa light chain (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimer (231-231":234-234")-bisdisulfide

lanadélumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* KLKB1 (kallikréine B 1, prékallikréine plasmatique (zymogène), kininogénine, facteur de Fletcher) clivé protéolytiquement par F12 (facteur FXII), kallikréine plasmatique active (EC 3.4.21.34)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -IGHG1*03, G1m3 (CH1 (123-220), charnière (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (123-451)], (225-213')-disulfure avec la chaîne légère kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimère (231-231":234-234")-bisdisulfure

lanadelumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* KLKB1 (kalikreína B 1, prekalikreína plasmática (zimógeno), kininogenina, factor de Fletcher) dividida proteolíticamente por F12 (factor FXII), kalikreína plasmática activa (EC 3.4.21.34)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -IGHG1*03, G1m3 (CH1 (123-220), bisagra (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (123-451)], (225-213')-disulfuro con la cadena ligera kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3(107'-213')]; dímeo (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGG LVQPGGSLRL SCAASGTFFS HYIMMWVRQA PGKLEWVSG 50
 IYSSGGITVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAYRR 100
 IGVPRRDEFD IWGQGMVTV SSASTKGPSV PFLAPSSKST SGGTAALGCL 150
 VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SGLYSLSSV VTPSSSLGT 200
 QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
 KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
 YNSTYRWSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKARGQPRE 350
 PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTP 400
 PVLDSDGSEF LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTKQSLSLSP 450
 G 451

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPST LSASVGRVIT ITCRASQGIS SWLAWYQQKP GKAPKLLIYK 50
 ASTLESGVPS RFGSGSGSTE FTLTISSLQP DDFATYYCQQ YNTYWTFGQG 100
 TKVEIKRTVA AFSVFIFFPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
 NALQSGNSQE SVTEQDSKDS TYLSSTLTLL SKADYEKHKV YACEVTHQGL 200
 SSPVTKSENR GEC 213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	149-205	266-326	372-430
	22"-96"	149"-205"	266"-326"	372"-430"
Intra-L (C23-C104)	23'-88"	133'-193"		
	23'''-88'''	133'''-193'''		
Inter-H-L (h 5-CL 126)	225-213'	225"-213"		
Inter-H-H (h 11, h 14)	231-231"	234-234"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

302, 302"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

laprituximabum #
laprituximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], chimeric monoclonal antibody;
 gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01 -IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (228-228":231-231")-bisdisulfide

laprituximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal chimérique;
 chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01 - IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (228-228":231-231")-bisdisulfure.

laprituximab

immunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal quimérico;

cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01)-(IGHD)-IGHJ4*01] [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01 -IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VAKPGASVKL SCRASGYTFT SYWMQWVKQR PGQGLECIGT 50
IYPGDGDTTY TQKFGKATL TADKSSSTAY MQLSSLRSED SAVVYCARYD 100
APGYAMYWG QGTLVTVSSA STRGPSVPFL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSVGH TFPVAVLQSSG LYSLSVTVT PSSSLGTQTY 200
ICNVNHPKPSN TKVDKKEPEK SCDKHTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTEP VTCVVVDVSH EDPEVKFINWY VDGVEVHNAK TKPREEQVNS 300
TYRIVSVLTV LHQDNLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPEVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG 448

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGVDRVT ITCRASQDIN NYLAWYQHQP GKGPKLLIHY 50
TSTLHPGIPSP RFGSGSGSRD YSFSISSLEP EDIATYYCLO YDNLLYTFGQ 100
GTALKIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L (C23-C104)	23"-88"	134"-194"		
	23"-88"	134"-194"		
Inter-H-L (h 5-CL 126)	222-214'	222"-214"		
Inter-H-H (h 11, h 14)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

laprituximabum emtansinum #
laprituximab emtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], chimeric monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-7*01)-(IGHD)-IGHJ4*01] [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (228-228":231-231")-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(*N*-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker forming a nonreducible thioether bond

For the *emtansine* part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

laprituximab emtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (Récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal chimérique conjugué au maytansinoïde DM1;

laprituximab emtansina

chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)), (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dimère (228-228'':231-231'')-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl-4-(*N*-maléimidométhyl) cyclohexane-1-carboxylate (SMCC) formant une liaison thioéther non réductible

Pour la partie *emtansine*, veuillez-vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

immunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal quimérico conjugado con el maitansinoide DM1;

cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)), (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dímero (228-228'':231-231'')-bisdisulfuro; conjugado, de 3 a 4 restos lisil por término medio, con el maitansinoide DM1 mediante el conector succinimidil-4-(*N*-maleimidometil) ciclohexano-1-carboxilato (SMCC) formando una unión tioéter no reducible

La fracción *emtansina* se pueden encontrar en el documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

Structure

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VAKPGASVKL SCKASGYTFT SYWMQWVKQR PGQGLECIGT 50
IYPGDGDTTY TQRFQKATL TADKSSSTAY MQLSSLRSSE SAVVYCARYD 100
APGYAMDYWG QGTLVTVSSA STRGPSVPPL APSSKSTSGG TAALGCLVKD 150
YFPEPVYYSW NSGALTSVGH TFPAPVLQSSG LYSLSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKEVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPTE VTCVVVDVSH EDPEVKFNWY VDGQEVVHNAK TKPREPEQNS 300
TYRIVSVLTV LHQDNLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPEPV 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSQSVV HEALHNHYTQ KSLSLSPG 448
    
```

Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPSS LSASVGRVIT ITCRASQDIN NYLAWYQHQP KGGPKLLIHY 50
TSTLHPGIPG RFGSGSGGRD YSFISISLEP EDIATYYCLQ YDNLLYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLNNFY PREAKVQWVK 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
    
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
 22"-96" 146"-202" 263"-323" 369"-427"

Intra-L (C23-C104) 23"-88" 134"-194"
 23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 222-214' 222"-214H"
 Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

An average of 3 to 4 lysyl being conjugated each to a drug linker / 3 à 4 lysylen moyenne sont conjugués à un linker-principe actif / Una media de 3 a 4 lisil están conjugadas a conectores-principio activo.

lenadogenum nolparvovecum #

lenadogene nolparvovec

a non-replicating single stranded DNA recombinant adeno-associated virus (rAAV) serotype 2 containing human wt MT-*ND4* cDNA that encodes NADH Dehydrogenase subunit 4, under the control of the cytomegalovirus immediate early (CMVie) promoter in an intron-containing expression cassette (beta globin intron, *HBB2*), flanked by the viral inverted terminal repeats from AAV2/2.

lénadogène nolparvovec

vecteur viral adéno-associé de sérotype 2 recombinant (rAAV) non-répliquant, avec un ADN monocaténaire contenant le gène wt MT-*ND4* codant pour la sous-unité 4 de la NADH déshydrogénase humaine, sous le contrôle d'un cytomégalovirus immédiat précoce dans un intron contenant la cassette d'expression (intron bêta-globine, *HBB2*), flanqué de répétitions inverses dérivées du virus adéno-associé de sérotype 2

lenadogén nolparvovec

vector viral adeno-asociado de serotipo 2 recombinante (rAAV) no replicativo, con un ADN monocatenario que contiene el gen wt MT-*ND4* que codifica para la subunidad 4 de la NADH deshidrogenasa humano, bajo el control de un promotor inmediato temprano del citomegalovirus en un intron que contiene el cassette de expresión (intron beta-globin, *HBB2*), flanqueado de repeticiones inversas derivadas del virus adeno-asociado del serotipo 2

leniolisibum

leniolisib


1-[(3*S*)-3-({6-[6-methoxy-5-(trifluoromethyl)pyrimidin-3-yl]-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

léniolisib

1-[(3*S*)-3-({6-[6-méthoxy-5-(trifluorométhyl)pyrimidin-3-yl]-5,6,7,8-tétrahydropyrido[4,3-*d*]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

leniolisib


1-[(3*S*)-3-({6-[6-metoxi-5-(trifluorometil)pirimidin-3-il]-5,6,7,8-tetrahidropirido[4,3-*d*]pirimidin-4-il}amino)pirrolidin-1-il]propan-1-ona

C₂₁H₂₅F₃N₆O₂**levoketoconazolum**

levoketoconazole



1-[4-[4-((2*S*,4*R*)-2-(2,4-dichlorophenyl)-2-[(1*H*-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl)methoxy)phenyl]piperazin-1-yl]ethan-1-one

- lévokétoconazole 1-{4-[4-((2*S*,4*R*)-2-(2,4-dichlorophényl)-2-[(1*H*-imidazol-1-yl)méthyl]-1,3-dioxolan-4-yl)méthoxy)phényl]pipérazin-1-yl}éthan-1-one
- levoketoconazol 1-{4-[4-((2*S*,4*R*)-2-(2,4-diclorofenil)-2-[(1*H*-imidazol-1-il)metil]-1,3-dioxolan-4-il)metoxi)fenil]pipérazin-1-il}etan-1-ona





lorlatinibum

- lorlatinib (10*R*)-7-amino-12-fluoro-2,10,16-triméthyl-15-oxo-10,15,16,17-tétrahydro-2*H*-4,8-méthénopyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotétradécine-3-carbonitrile
- lorlatinib (10*R*)-7-amino-12-fluoro-2,10,16-triméthyl-15-oxo-10,15,16,17-tétrahydro-2*H*-4,8-méthénopyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotétradécine-3-carbonitrile
- lorlatinib (10*R*)-7-amino-12-fluoro-2,10,16-triméthyl-15-oxo-10,15,16,17-tétrahydro-2*H*-4,8-méthénopyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotétradécine-3-carbonitrile



lumateperonum

- lumateperone 1-(4-fluorophényl)-4-[(6*bR*,10*aS*)-3-méthyl-2,3,6*b*,9,10,10*a*-hexahydro-1*H*-pyrido[3',4':4,5]pyrrolo[1,2,3-*de*]quinoxalin-8(7*H*)-yl]butan-1-one
- lumatéperone 1-(4-fluorophényl)-4-[(6*bR*,10*aS*)-3-méthyl-2,3,6*b*,9,10,10*a*-hexahydro-1*H*-pyrido[3',4':4,5]pyrrolo[1,2,3-*de*]quinoxalin-8(7*H*)-yl]butan-1-one
- lumateperona 1-(4-fluorofenil)-4-[(6*bR*,10*aS*)-3-metil-2,3,6*b*,9,10,10*a*-hexahidro-1*H*-pirido[3',4':4,5]pirrolo[1,2,3-*de*]quinoxalin-8(7*H*)-il]butan-1-ona

**mesmulogenum ancovaccineum #**

mesmulogene ancovaccine

a non-replicating recombinant vaccinia virus, based on the Modified Vaccinia Virus Ankara (MVA) strain, carrying sequences coding for the expression of the human Mucine 1 (MUC1) antigen and human Interleukin 2 (IL2), under the control of pH5R and p7.5 vaccinia promoters, respectively.

mesmulogène ancovaccine

vecteur viral recombinant non-répliquant de la vaccine, dérivé du virus de la vaccine modifié Ankara, contenant les séquences d'ADN codant pour l'expression de l'antigène de la Mucine 1 et de l'interleukine 2 humaine, sous le contrôle des promoteurs pH5R et p7.5, respectivement

mesmulogén ancovaccine

vector viral recombinante no replicativo de la vacuna, derivado de la cepa del virus de la vacuna modificada Ankara, que contiene las secuencias del ADN que codifica para la expresión del antígeno de la Mucina 1 (MUC1) y de la interleukina 2 humana (IL2), bajo el control de los promotores vaccinia pH5R y p7.5, respectivamente

mipeginterferonum alfa-2b #

mipeginterferon alfa-2b

$N^{2.1}, N^{6.Lys}$ -oligo(N -{2-[ω -methoxypoly(oxyethylene)- α -yl]acetyl}- N -[α -methylpoly(oxyethylene)- ω -yl]glycyl)human interferon alpha-2b, with an average number of 5 substituted among 11 amino groups (one N -terminal and 10 lysine N^6), the protein part being produced in *Pichia pastoris* (*Komagataella pastoris*)

The relative molecular mass of the polyethylene glycol part can be indicated after the INN, for example: mipeginterferon alfa-2b (40 kDa)

mipèginterféron alfa-2b


$N^{2.1}, N^{6.Lys}$ -oligo(N -{2-[ω -méthoxypoly(oxyéthylène)- α -yl]acétyl}- N -[α -méthylpoly(oxyéthylène)- ω -yl]glycyl)interféron alpha-2b humain, une moyenne de 5 azotes parmi les 11 (un N -terminal et 10 lysines N^6) sont substitués, la partie protéique étant produite par *Pichia pastoris* (*Komagataella pastoris*)

La masse molaire de la partie polyéthylène glycol peut être indiquée après la DCI, par exemple: mipèginterféron alfa-2b (40 kDa)

mipeginterferón alfa-2b

$N^{2,1}, N^{6, \text{Lys}}$ -oligo(*N*-{2-[ω -metoxipoli(oxietileno)- α -il]acetil}-*N*-[α -metilpoli(oxietileno)- ω -il]glicil)interferón alfa-2b humano, con una media de 5 grupos amino sustituidos entre los 11 (un *N*-terminal y 10 lisinas N^6), la parte proteica es producida por *Pichia pastoris* (*Komagataella pastoris*)

La masa molar de la parte polietilen glicol puede ser indicada después de la DCI, por ejemplo: mipeginterferón alfa-2b (40 kDa).





mirvetuximabum #
 mirvetuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], chimeric monoclonal antibody; gamma1 heavy chain (1-447) [*Mus musculus* VH (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfide with kappa light chain (1'-218') [*Mus musculus* V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (227-227'':230-230'')-bisdisulfide

mirvétuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* FOLR1 (récepteur 1 du folate, récepteur alpha du folate, FR-alpha, protéine de l'adulte liant le folate, FBP, antigène MOv18 associé à des tumeurs ovariennes)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-447) [*Mus musculus* VH (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfure avec la chaîne légère kappa (1'-218') [*Mus musculus* V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (227-227'':230-230'')-bisdisulfure

mirvetuximab	<p>inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> FOLR1 (receptor 1 de folato, receptor alfa de folato, FR-alpha, proteína del adulto que liga el folato, FBP, antígeno Mov18 asociado a tumores ováricos)], anticuerpo monoclonal quimérico;</p> <p>cadena pesada gamma1 (1-447) [<i>Mus musculus</i> VH (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -<i>Homo sapiens</i> IGHG1*01, Gm17, 1 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfuro con la cadena ligera kappa (1'-218') [<i>Mus musculus</i> V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-111') -<i>Homo sapiens</i> IGKC*01, Km3 (112'-218')]; dímero (227-227":230-230")-bisdisulfuro</p> <p>Heavy chain / Chaîne lourde / Cadena pesada</p> <pre> QVQLVQSGAE VVKPGASVKI SCKASGYTFT GYFMNWVKQS PGQSLEWIGR 50 IHPYDGDTFY NQKFQGKATL TVDKSSNTAH MELLSLTSED FAVYYCTRYD 100 GSRAMDYWGQ GTTIVTVSSAS TKGPSVFLPA PSSKSTSGGT AALGCLVKDY 150 FPEPVTVSWN SGALTVGVHT FPAVLQSSGL YSLSSVTVF SSSLGTQTYI 200 CNVNHKPSNT KVDKKEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250 TLMISRTPPEV TCVVVDVSH EPEVKFNWYV DGEVHNAKT KPREEQYNST 300 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350 LTPPSRDELDT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD 400 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG 447 </pre> <p>Light chain / Chaîne légère / Cadena ligera</p> <pre> DIVLTQSPLE LAVSLGQPAI ISCKASQSVS FAGTSLMHWY HQKPGQQPRL 50 LIYRASNL EA GVPDRFSGSG SKTDFLTLS PVEAEDAATY YCQPSREXPY 100 TFGGGTKLEI KRTVAAPS VF IFPPSDEQLK SGTASVVC LL NNFYPREAKV 150 QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200 THQGLSSPVT KSFNRGEC 218 </pre> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <table border="0"> <tr> <td>Intra-H (C23-C104)</td> <td>22°-96"</td> <td>145°-201"</td> <td>262°-322"</td> <td>368°-426"</td> </tr> <tr> <td>Intra-L (C23-C104)</td> <td>23°-92"</td> <td>138°-198"</td> <td>23°-92"</td> <td>138°-198"</td> </tr> <tr> <td>Inter-H-L (h 5-CL 126)</td> <td>221°-218'</td> <td>221°-218'</td> <td></td> <td></td> </tr> <tr> <td>Inter-H-H (h 11, h 14)</td> <td>227°-227"</td> <td>230-230"</td> <td></td> <td></td> </tr> </table> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación</p> <p>H CH2 N84.4: 298, 298"</p> <p>Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados</p>	Intra-H (C23-C104)	22°-96"	145°-201"	262°-322"	368°-426"	Intra-L (C23-C104)	23°-92"	138°-198"	23°-92"	138°-198"	Inter-H-L (h 5-CL 126)	221°-218'	221°-218'			Inter-H-H (h 11, h 14)	227°-227"	230-230"		
Intra-H (C23-C104)	22°-96"	145°-201"	262°-322"	368°-426"																	
Intra-L (C23-C104)	23°-92"	138°-198"	23°-92"	138°-198"																	
Inter-H-L (h 5-CL 126)	221°-218'	221°-218'																			
Inter-H-H (h 11, h 14)	227°-227"	230-230"																			
mizagliflozinum mizagliflozin	<p>3-[[3-(4-[[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy)propyl]amino]-2,2-dimethylpropanamide</p>																				
mizagliflozine	<p>3-[[3-(4-[[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)-1H-pyrazol-4-yl]methyl]-3-méthylphénoxy)propyl]amino]-2,2-diméthylpropanamide</p>																				
mizagliflozina	<p>3-[[3-(4-[[3-(β-D-glucopiranosiloxi)-5-(propan-2-il)-1H-pirazol-4-il]metil]-3-metilfenoxi)propil]amino]-2,2-dimetilpropanamida</p>																				

**nafithromycinum**

nafithromycin



(3*R*,3'¹*Z*,3*aS*,4*R*,6*R*,8*R*,9*R*,10*R*,12*R*,15*R*,15*aS*)-15-ethyl-8-methoxy-4,6,8,10,12,15*a*-hexamethyl-2,5,11,13-tetraoxo-*N'*-{(1*S*)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]éthoxy}-9-[[3,4,6-trideoxy-3-(diméthylamino)-β-*D*-xylohexopyranosyl]oxy}tétradécahy-dro-2*H*-furo[2,3-*c*]oxacyclotétradécine-3-carboximidamide

nafithromycine

(3*R*,3'¹*Z*,3*aS*,4*R*,6*R*,8*R*,9*R*,10*R*,12*R*,15*R*,15*aS*)-15-éthyl-8-méthoxy-4,6,8,10,12,15*a*-hexaméthyl-2,5,11,13-tétraoxo-*N'*-{(1*S*)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]éthoxy}-9-[[3,4,6-tridéoxy-3-(diméthylamino)-β-*D*-xylohexopyranosyl]oxy}tétradécahy-dro-2*H*-furo[2,3-*c*]oxacyclotétradécine-3-carboximidamide

nafitromicina

(3*R*,3'¹*Z*,3*aS*,4*R*,6*R*,8*R*,9*R*,10*R*,12*R*,15*R*,15*aS*)-15-etil-8-metoxi-4,6,8,10,12,15*a*-hexametil-2,5,11,13-tetraoxo-*N'*-{(1*S*)-1-[5-(piridin-2-il)-1,3,4-tiadiazol-2-il]etoxi}-9-[[3,4,6-tridesoxi-3-(dimetilamino)-β-*D*-xilo-hexopiranosil]oxi}tétradecahidro-2*H*-furo[2,3-*c*]oxaciclótétradecina-3-carboximidamida

**naratuximabum #**

naratuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD37 (tetraspanin-26, TSPAN26)], chimeric monoclonal antibody;

gamma1 heavy chain (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (224-224":227-227")-bisdisulfide

naratuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD37 (tétraspagine-26, TSPAN26)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), charnière (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (224-224":227-227")-bisdisulfure

naratuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfuro con cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (224-224":227-227")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQVQESGPG LVAPSQTLSI TCTVSGFSLT TSGVSWVRQP PGKGLEWLGV 50
IWGDGSTNYH PSLKSRLSIK KDHSKSQVFL KLNSLTAADT ATYYCARGGY 100
SLAHWGQGTLL VTVSSASTKG PSVFPLAPSS KTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVPEKSCDK THTCPPCPAP ELLGGPSVFL FPPPKDITLM 250
ISRTPFVTKCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNKKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLF 350
PSRDELTKNQ VSLTCLVKG F YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMEAL HNHYTKKLS LSPG 444

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSVSVGERVT ITCRASENIR SNLAWYQQKPK GKSPKLLVNV 50
ATNLADGVPS RFGSGSGGTD YSLKINSIQP EDFGTYYCQH YWGTWTWFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	142-198	259-319	365-423
	22"-95"	142"-198"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (h 5-CL 126)	218-214'	218"-214"		
Inter-H-H (h 11, h 14)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295^a

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

naratuximabum emtansinum #

naratuximab emtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens*CD37 (tetraspanin-26, TSPAN26)], chimeric monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(*N*-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker forming a nonreducible thioether bond

For the *emtansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

naratuximab emtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens*CD37 (tétraspanine-26, TSPAN26)], anticorps monoclonal chimérique conjugué au maytansinoïde DM1; chaîne lourde gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), charnière (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl-4-(*N*-maléimidométhyl) cyclohexane-1-carboxylate (SMCC) formant une liaison thioéther non réductible

Pour la partie *emtansine*, veuillez-vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

naratuximab emtansina

immunoglobulina G1-kappa, anti-[*Homo sapiens*CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoclonal quimérico conjugado con maitansinoide DM1; cadena pesada gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfuro con cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro; conjugado, en una media de 3 a 4 restos lisil, con maitansinoide DM1 mediante un conector succinimidil-4-(*N*-maleimidometil) ciclohexano-1-carboxilato (SMCC) formando una unión tioéter no reducible

La fracción *emtansina* se pueden encontrar en el documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

Heavy chain / Chaîne lourde / Cadena pesada

QVQVQESGPG LVAPSQTLST TCTVSGFSLT TSGVSWVRQP PGKGLEWLGV 50
 IWGDGSTNYH PSLKSRLSIK KDHSKSQVFL KLNLSLTAAD ATYYCARGGY 100
 SLAHWQQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
 PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
 NHHKPSNTKVD KKVPEKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
 ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTRP BEQYNSTYRV 300
 VSVLTVLHQD WLNKKEYKCK VSNKALPAPI ERTISKAKGQ PREPQVYTLF 350
 PSRDELTKNQ VSLTCLVKGK YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
 SFFLYSKLTV DRSRWQQGNV FSCSVHREAL HNHYTQKSLG LSPG 444

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSVSVGERVT ITCRASENIR SNLAWYQQKPK GKSPKLLNVV 50
 ATNLDAGVPS RFGSGSGSTD YSLKINSLOP EDFGTYYCQH YWGTTWTFGQ 100
 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-95 142-198 259-319 365-423
 22"-95" 142"-198" 259"-319" 365"-423"

Intra-L (C23-C104) 23'-88' 134'-194'
 23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 218-214' 218"-214"

Inter-H-H (h 11, h 14) 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

An average of 3 to 4 lysyl being conjugated each to a drug linker / 3 à 4 lysyl en moyenne sont conjugués à un linker-principe actif / Una media de 3 a 4 lisil están conjugadas a conectores-principio activo.

navamepentum

navamepent

propan-2-yl (5*S*,8*E*,10*E*,12*R*)-5,12-dihydroxypentadeca-8,10-diene-6,14-dienoate


navamépent

(5*S*,8*E*,10*E*,12*R*)-5,12-dihydroxypentadéca-8,10-diène-6,14-diénoate de propan-2-yle

navamepent

(5*S*,8*E*,10*E*,12*R*)-5,12-dihidroxipentadeca-8,10-dieno-6,14-diinoato de propan-2-ilo

C₁₈H₂₄O₄



navicixizumabum

navicixizumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* DLL4 (delta-like 4)] and anti-[*Homo sapiens* VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized and chimeric monoclonal antibody, bispecific;

	<p>gamma2 heavy chain, humanized anti-DLL4 (1-445) [humanized VH (<i>Homo sapiens</i> IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -<i>Homo sapiens</i> IGHG2*01 (CH1 (120-217), hinge (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133-218')-disulfide with kappa light chain, chimeric (1'-218') [chimeric V-KAPPA (<i>Mus musculus</i> IGKV3-2*01 -<i>Homo sapiens</i> IGKJ1*01) [10.3.9] (1'-111') -<i>Homo sapiens</i> IGKC*01, Km3 (112'-218')];</p> <p>gamma2 heavy chain, humanized anti-VEGFA (1-447) [humanized VH (<i>Homo sapiens</i> IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG2*01 (CH1(122-219), hinge (220-231), CH2 (232-340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfide with kappa light chain, chimeric (1'''-218''') [chimeric V-KAPPA (<i>Mus musculus</i> IGKV3-2*01 -<i>Homo sapiens</i> IGKJ1*01) [10.3.9] (1'''-111''') -<i>Homo sapiens</i> IGKC*01, Km3 (112'''-218''')];</p> <p>dimer (221-223":222-224":225-227":228-230")-tetrakisdisulfide</p>
navicixizumab	<p>immunoglobuline G2-kappa, anti-[<i>Homo sapiens</i> DLL4 (delta-like 4)] et anti-[<i>Homo sapiens</i> VEGFA (facteur de croissance A de l'endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé et chimérique, bispécifique;</p> <p>chaîne lourde gamma2, humanisée anti-DLL4 (1-445) [VH humanisé (<i>Homo sapiens</i> IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -<i>Homo sapiens</i> IGHG2*01 (CH1 (120-217), charnière (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133-218')-disulfure avec la chaîne légère kappa, chimérique (1'-218') [V-KAPPA chimérique (<i>Mus musculus</i> IGKV3-2*01 -<i>Homo sapiens</i> IGKJ1*01) [10.3.9] (1'-111') -<i>Homo sapiens</i> IGKC*01, Km3 (112'-218')];</p> <p>chaîne lourde gamma2, humanisée anti-VEGFA (1-447) [VH humanisé (<i>Homo sapiens</i> IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG2*01 (CH1 (122-219), charnière (220-231), CH2 (232-340), CH3 (341-445) E13>K (357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfure avec la chaîne légère kappa, chimérique (1'''-218''') [V-KAPPA chimérique (<i>Mus musculus</i> IGKV3-2*01 -<i>Homo sapiens</i> IGKJ1*01) [10.3.9] (1'''-111''') -<i>Homo sapiens</i> IGKC*01, Km3 (112'''-218''')]; dimère (221-223":222-224":225-227":228-230")-tétrakisdisulfure</p>
navicixizumab	<p>immunoglobulina G2-kappa, anti-[<i>Homo sapiens</i> DLL4 (delta-like 4)] y anti-[<i>Homo sapiens</i> VEGFA (factor de crecimiento A del endotelio vascular, VEGF-A, VEGF)], anticuerpo humanizado y quimérico, biespecifico;</p>

cadena pesada gamma2, humanizada anti-DLL4 (1-445) [VH humanizado (*Homo sapiens* IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG2*01 (CH1 (120-217), bisagra (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133-218')-disulfuro con la cadena ligera kappa, quimérica (1'-218') [V-KAPPA quimérico (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218'))]; cadena pesada gamma2, humanizada anti-VEGFA (1-447) [VH humanizado (*Homo sapiens* IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1(122-219), bisagra (220-231), CH2 (232-340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfuro con la cadena ligera kappa, quimérica (1'''-218''') [V-KAPPA quimérico (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'''-111''') -*Homo sapiens* IGKC*01, Km3 (112'''-218''')]; dímero (221-223":222-224":225-227":228-230")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada (anti-DLL4, 1-445)
 QVQLEWQSGAE FVSKPGLSGLTQ RYVYIHWKQK PGQGLEWIGY 50
 ISNYNRATNY NQKFKGRVTF TDDTSTSTAY MELSLRSDD TAVYICARDY 100
 DYDVGMDVWG OGLTIVTVSSA STKGPSVFLP APCSRSTSES TAALGCLVKD 150
 YFPFVTVSW NSGALTSGVH TEPAYVLOSSG LYSLSSTVTV ESSNFGICTY 200
 TCVNVDHPSN TSYDKVTEK CVVECFCPA FVYAGPSVFL FPPKPKDTLM 250
 ISRTPEVTCV VVDVSHEDPE VOENWYVDGV EVHNAKTKPR BEQFNSTFRV 300
 VSVLTVVHDQ WLNKREYKCK VSNKGLPAPI EKIISKTKGO PREPOVYITLP 350
 PQRREMTKQ VSLTCLVPEF YPSDIAVWEV SNGQENNYK TTPPLDSDG 400
 SFPLYSELTV DKSRWQQGNV FSCSVMEAL HNHYTQKSL SLSPGK 445

Heavy chain / Chaîne lourde / Cadena pesada (anti-VEGFA, 1'-447)
 QVQLEWQSGAE VKKPGASVKV SCKASGYTFT NYMHWVROA PGQGLEWMDG 50
 INPSNGRTSY KEKFKRRRVTL SVDKSSSTAY MELSLRSDD TAVYFCTIHY 100
 DDKYYPIMDY WQGLTIVTVS SASTKGPSVF FLAPCSRSTS ESTAALGCLV 150
 KDYFPEFVTV SWNSGALTSG VHTFPAVLSG SGLYSLSSTV TVPSSNFTQ 200
 TYTCNVDPKPS SNTKVDKTEV RKCCVECPCC PAPPVAGPSV FLFPPKPKRDT 250
 LMISRTPEVT CVVVDVSHED PEVOFNWYVD GVEVHNAKT PRBEOFNSTF 300
 RVVSVLTVVH ODWLNKREYK CKVSNKGLPA PIEKTI SKTK GQPREPOVYIT 350
 LPPRREMTKQ NOVSLTCLVYK GFVPSDIAVE WESNGQENNYK YTPPLDSDG 400
 DGSFFLYSKL TVDKSRWQQG NVFSCSVMEH ALHNHYTEK SLSLSPGK 447

Light chain / Chaîne légère / Cadena ligera
 DFWMTQSPDS LAVSLGERAT ISCRASESDV NYGISFMKWF OOKPGQPPKL 50
 LIYAAASNOGS GVPDRFSGSG SGTDFLTLS SLOAEDVAVY YCOOSKEVWPW 100
 TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCCL NNFYPREAKV 150
 QKRYDALQS GKVSLTCLVYK GFVPSDIAVE WESNGQENNYK YTPPLDSDG 200
 THQGLSSPVT KSFNRGEC

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 146-202 259-319 365-423
 22'-96" 148"-204" 261"-321" 367"-425"
 Intra-L (C23-C104) 23'-97" 138"-198"
 23"-92" 138"-198"
 Inter-H-L (CH1 10-CL 126) 133-218' 135'-218"
 Inter-H-H (h 4, h 5, h 11, h 14) 221-223" 222-224" 225-227" 228-230"

*In addition to the isoform A, isoform B characterized by two inter-H-H (h 5-CH1 10) (222-135', 224'-133) and two inter-H-L (h 4-CL 126) (221-218', 223'-218"), instead of the inter-H-H (h 4-h 4, h 5-h 5) and the two inter-H-L (CH1 10-CL 126), and two isoforms A/B characterized by one inter-H-H (h 4-CH1 10) and one inter-H-L (h 4-CL 126) (221-135' and 223'-218", respectively, in one isoform A/B, 223'-133 and 221-218", respectively in the other one), instead of the inter-H-H (h 4-h 4) and one inter-H-L (CH1 10-CL 126). It is not excluded that other disulfide bridges may occur between the same cysteines.

*En plus de l'isoforme A, l'isoforme B caractérisée par un inter-H-H (h 5-CH1 10) (222-135', 224'-133) et deux inter-H-L (h 4-CL 126) (221-218', 223'-218"), au lieu des inter-H-H (h 4-h 4, h 5-h 5) et des deux inter-H-L (CH1 10-CL 126), et deux isoformes A/B caractérisées par un inter-H-H (h 4-CH1 10) et un inter-H-L (h 4-CL 126) (221-135' et 223'-218", respectivement, dans une isoforme A/B, 223'-133 et 221-218", respectivement, dans l'autre), au lieu de l'inter-H-H (h 4-h 4) et d'un inter-H-L (CH1 10-CL 126). Il n'est pas exclu que d'autres ponts disulfures existent entre les mêmes cystéines.

*Además de la isoforma A, isoforma B caracterizada por un inter-H-H (h 5-CH1 10) (222-135', 224'-133) y dos inter-H-L (h 4-CL 126) (221-218', 223'-218"), en lugar de los inter-H-H (h 4-h 4, h 5-h 5) y de los dos inter-H-L (CH1 10-CL 126), y dos isoformas A/B caracterizadas por un inter-H-H (h 4-CH1 10) y un inter-H-L (h 4-CL 126) (221-135' et 223'-218", respectivamente, dentro una isoforma A/B, 223'-133 et 221-218", respectivamente, dentro el otra), en lugar de l'inter-H-H (h 4-h 4) y de uno inter-H-L (CH1 10-CL 126). No se excluye que otros puentes disulfuro existan entre las mismas cisteínas.

nazartinibum
 nazartinib


N-(7-chloro-1-[(3*R*)-1-[(2*E*)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-1*H*-benzimidazol-2-yl)-2-methylpyridine-4-carboxamide

nazartinib

N-(7-chloro-1-[(3*R*)-1-[(2*E*)-4-(diméthylamino)but-2-énoyl]azépan-3-yl]-1*H*-benzimidazol-2-yl)-2-méthylpyridine-4-carboxamide

nazartinib

N-(7-cloro-1-((3*R*)-1-[(2*E*)-4-(dimetilamino)but-2-enil]azepan-3-il)-1*H*-benzimidazol-2-il)-2-metilpiridina-4-carboxamida

 $C_{26}H_{31}ClN_6O_2$


nicodicosapentum

nicodicosapent


N-{2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)-icosa-5,8,11,14,17-pentaenamido]ethyl}pyridine-3-carboxamide

nicodicosapent

N-{2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)-icosa-5,8,11,14,17-pentaénamido]éthyl}pyridine-3-carboxamide

nicodicosapent

N-{2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)-icosa-5,8,11,14,17-pentaenamido]etil}piridina-3-carboxamida

 $C_{28}H_{39}N_3O_2$


nolasibanum

nolasiban


[(2*S*,4*Z*)-2-(hydroxymethyl)-4-(methoxyimino)pyrrolidin-1-yl](2'-methyl[1,1'-biphenyl]-4-yl)methanone

nolasiban

[(2*S*,4*Z*)-2-(hydroxyméthyl)-4-(méthoxyimino)pyrrolidin-1-yl](2'-méthyl[1,1'-biphényl]-4-yl)méthanone

nolasibán

(2*S*,4*Z*)-2-(hidroximetil)-4-(metoxiimino)pirrolidin-1-il](2'-metil[1,1'-bifenil]-4-il)metanona

 $C_{20}H_{22}N_2O_3$


oliceridinum


oliceridine

N-[(3-methoxythiophen-2-yl)methyl]-2-[(9*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethan-1-amine

olicéridine *N*-[(3-méthoxythiophén-2-yl)méthyl]-2-[(9*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]décan-9-yl]éthan-1-amine

oliceridina *N*-[(3-metoxitiofen-2-il)metil]-2-[(9*R*)-9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etan-1-amina

$C_{22}H_{30}N_2O_2S$




olmutinibum

olmutinib *N*-[3-({2-[4-(4-méthylpiperazin-1-yl)anilino]thieno[3,2-*d*]pyrimidin-4-yl}oxy)phényl]prop-2-enamide

olmutinib *N*-[3-({2-[4-(4-méthylpipérazin-1-yl)anilino]thiéno[3,2-*d*]pyrimidin-4-yl}oxy)phényl]prop-2-énamide

olmutinib *N*-[3-({2-[4-(4-metilpiperazina-1-il)anilino]tieno[3,2-*d*]pirimidin-4-il}oxi)fenil]prop-2-enamida

$C_{26}H_{26}N_6O_2S$




olumacostatum glasaretilum

olumacostat glasaretil 2-[(2-étoxy-2-oxoéthyl)(méthyl)amino]-2-oxoéthyl 5-(tétradécyloxy)furane-2-carboxylate

olumacostat glasarétil 5-(tétradécyloxy)furane-2-carboxylate de 2-[(2-éthoxy-2-oxoéthyl)(méthyl)amino]-2-oxoéthyle

olumacostat glasaretilo 5-(tetradeciloxi)furane-2-carboxilato de 2-[(2-etoxi-2-oxoetil)(metil)amino]-2-oxoetilo

$C_{26}H_{43}NO_7$



omidenepagum

omidenepag


{{6-[(N-[[4-(1*H*-pyrazol-1-yl)phényl]méthyl]pyridine-3-sulfonamido)méthyl]pyridin-2-yl}amino)acetic acid

omidénépag

acide {{6-[(N-[[4-(1*H*-pyrazol-1-yl)phényl]méthyl]pyridine-3-sulfonamido)méthyl]pyridin-2-yl}amino)acétique

omidenepag

ácido {{6-[(N-[[4-(1*H*-pirazol-1-il)fenil]metil]piridina-3-sulfonamido)metil]piridin-2-il}amino)acético

C₂₃H₂₂N₆O₄S**oteseconazolom**

oteseconazole


(2*R*)-2-(2,4-difluorophényl)-1,1-difluoro-3-(1*H*-1,2,3,4-tétrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroéthoxy)phényl]pyridin-2-yl}propan-2-ol

otéséconazole

(2*R*)-2-(2,4-difluorophényl)-1,1-difluoro-3-(1*H*-1,2,3,4-tétrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroéthoxy)phényl]pyridin-2-yl}propan-2-ol

oteseconazol

(2*R*)-2-(2,4-difluorofenil)-1,1-difluoro-3-(1*H*-1,2,3,4-tétrazol-1-il)-1-{5-[4-(2,2,2-trifluoroetoxi)fenil]piridin-2-il}propan-2-ol

C₂₃H₁₆F₇N₅O₂**pibrentasvirum**

pibrentasvir


dimethyl *N,N*-([[(2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorophényl)piperidin-1-yl]phényl]pyrrolidine-2,5-diyl]bis{(6-fluoro-1*H*-benzimidazole-5,2-diyl)}[(2*S*)-pyrrolidine-2,1-diyl]][(2*S*,3*R*)-3-méthoxy-1-oxobutane-1,2-diyl])dicarbamate

pibrentasvir

N,N'-((2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorophényl)pipéridin-1-yl]phényl}pyrrolidine-2,5-diyl)bis{(6-fluoro-1*H*-benzimidazole-5,2-diyl)[(2*S*)-pyrrolidine-2,1-diyl][(2*S*,3*R*)-3-méthoxy-1-oxobutane-1,2-diyl]}dicarbamate de diméthyle

pibrentasvir

N,N'-((2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorofenil)piperidin-1-il]fenil}pirrolidina-2,5-diil)bis{(6-fluoro-1*H*-benzimidazol-5,2-diil)[(2*S*)-pirrolidina-2,1-diil][(2*S*,3*R*)-3-metoxi-1-oxobutano-1,2-diil]}dicarbamato de dimetil

 $C_{57}H_{65}F_6N_{10}O_8$
**prexasertibum**

prexasertib


5-({5-[2-(3-aminopropoxy)-6-méthoxyphényl]-1*H*-pyrazol-3-yl}amino)pyrazine-2-carbonitrile

prexasertib

5-({5-[2-(3-aminopropoxy)-6-méthoxyphényl]-1*H*-pyrazol-3-yl}amino)pyrazine-2-carbonitrile

prexasertib

5-({5-[2-(3-aminopropoxy)-6-metoxifenil]-1*H*-pirazol-3-il}amino)pirazina-2-carbonitrilo

 $C_{18}H_{19}N_7O_2$


prexigebersenum

prexigebersen

2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-
2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-
(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-
2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-
2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-
thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-
2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-
thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidine

prexigébersen

2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-
2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-
(3'→5')-thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-
2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-
2'-déoxyguanylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-
thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-
2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-
thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidine

prexigebersén

2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxiadenilil-
(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-
2'-desoxiguanilil-(3'→5')-2'-desoxiguanilil-(3'→5')-
2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-
2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxiguanilil-
(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-
timidilil-(3'→5')-timidilil-(3'→5')-2'-desoxicitidina

 $C_{177}H_{224}N_{63}O_{110}P_{17}$

(3'-5')d(A-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C)

prezalumabum #

prezalumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* ICOSL
(inducible T-cell co-stimulatory ligand, B7 homologue 2,
B7H2, B7-H2, B7-related protein 1, B7RP1, B7RP-1,
CD275)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain (1-447) [*Homo sapiens* VH (IGHV3-
7*01 (98.00%) -(IGHD) -IGHJ2*01 [8.8.14] (1-121) -
IGHG2*01, G2m.. (CH1 (122-219), hinge (220-231), CH2
(232-340), CH3 (341-445), CHS (446-447)) (122-447)],
(135-214')-disulfide with kappa light chain (1'-214') [*Homo*
sapiens V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01
[6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (223-
223":224-224":227-227":230-230")-tetrakisdisulfide

préalumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* ICOSL
(ligand inductible co-stimulateur des cellules T, homologue
2 du B7, B7H2, B7-H2, protéine 1 apparentée au B7,
B7RP1, B7RP-1, CD275)], *Homo sapiens* anticorps
monoclonal;
chaîne lourde gamma2 (1-447) [*Homo sapiens* VH
(IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01 [8.8.14] (1-
121) -IGHG2*01, G2m.. (CH1 (122-219), charnière (220-
231), CH2 (232-340), CH3 (341-445), CHS (446-447))
(122-447)], (135-214')-disulfure avec la chaîne légère
kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV2D-16*01
(97.90%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
214')]; dimère (223-223":224-224":227-227":230-230")-
tétrakisdisulfure

prezalumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* ICOSL (ligando inducible co-estimulador de las células T, B7 homólogo 2, B7H2, B7-H2, proteína 1 relacionada con la B7, B7RP1, B7RP-1, CD275)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma2 (1-447) [*Homo sapiens* VH (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-121) -IGHG2*01, G2m.. (CH1 (122-219), bisagra (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (223-223":224-224":227-227":230-230")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYMWSWVRQA PGKLEWVAY 50
IKQDNEKYY VDSVKGRFTI SRDNAKNSLY LQMSLRAED TAVYVCAREG 100
ILWFGDLPTF WQGGTLVTVS SASTKGPVSFV FLAPCSRSTS ESTAALGCLV 150
KDYFPEPFTV SWNSGALTSV VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ 200
TYTCNVDHKP SNTKVDKTVK RKCCVECPFC PAPPVAGPSV FLFPKPKDPT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF 300
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTI SSKTK GQPREPQVYT 350
LPPSREEMTK NOVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPMPLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVHME ALHNYTQKRS LSLSPGK 447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRTV ITCRASQGIS NWLAWYQOKP EKAPKSLIYA 50
ASSLQSGVPS RFGSGSGTD FTLTISSLOP EDFATYYCQQ YDSYPRTFGQ 100
GTKVEIKRTV AAPSVFI FPP SDEQLKSGTA SVVCLLNPFY PREAKVQMKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	261-321	367-425
	22"-96"	148"-204"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (CH1 10-CL 126)	135-214'	135"-214"		
Inter-H-H (h 4, h 5, h 8, h 11)	223-223"	224-224"	227-227"	230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

297,297"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

redaporfinum

redaporfin



3,3',3",3'''-(7,8,17,18-tetrahydroporphyrin-5,10,15,20-tetrayl)tetrakis(2,4-difluoro-*N*-methylbenzenesulfonamide)

rédiaporfine

3,3',3",3'''-(7,8,17,18-tétrahydroporphyrin-5,10,15,20-tétrayl)tétrakis(2,4-difluoro-*N*-méthylbenzènesulfonamide)

redaporfina

3,3',3",3'''-(7,8,17,18-tetrahidroporfirin-5,10,15,20-tetraíl)tetrakis(2,4-difluoro-*N*-metilbencenosulfonamida)



refanezumabum #
refanezumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MAG (myelin associated glycoprotein, sialic acid binding Ig-like lectin 4A, SIGLEC4A, SIGLEC-4A)], humanized monoclonal antibody;
gamma1 heavy chain (1-456) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (127-224), hinge (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456))] (127-456)], (229-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219'))]; dimer (235-235":238-238")-bisdisulfide

réfanézumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MAG (glycoprotéine associée à la myéline, lectine 4A Ig-like liant l'acide sialique, SIGLEC4A, SIGLEC-4A)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-456) [humanisé VH (*Homo sapiens* IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (127-224), charnière (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456))] (127-456)], (229-219')- disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219'))]; dimère (235-235":238-238")-bisdisulfure

refanezumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MAG (glicoproteína asociada a la mielina, lectina de tipo inmunoglobulina 4A que se une al ácido siálico, SIGLEC4A, SIGLEC-4A)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-456) [VH humanizado (*Homo sapiens* IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -*Homo sapiens* IGHG1*01, G1m17.1 (CH1 (127-224), bisagra (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dímero (235-235":238-238")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGSE LKPGASVKV SCKASGYTFT NYGMNWRQA PGQGLEWMGW 50
INTYTGEPY ADDFTGRFVF SLDTSVSTAY LQISSLKAED TAVYGCARNP 100
INYYGINYEG YVMDYWGQGT LVTSSASTK GPSVFFPLAPS SKSTSGGTAA 150
LGLVKVDYFP EPVTVSWNSG ALTVSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELAGAPSVF 250
LFFPKPKDYL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNNKALPAP IEKTIKAKG 350
QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY 400
KTPFPVLDSD GSFFLYSKLT VDKSRWQGN VFCSCVMHEA LHNHYTQKSL 450
SLSPGK 456
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSHSVL YSSNQKNYLA WYQKPGQPP 50
KLLIYWASTR ESGVPDRFSG SGSSTDFTLT ISSLQAEDVA VYCHQYLSS 100
LTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK 150
VQWVKVDNALQ SGNSQESVTE QDSKDSYISL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNREGC 219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	153-209	270-330	376-434
	22"-96"	153"-209"	270"-330"	376"-434"
Intra-L (C23-C104)	23'-94'	139'-199'		
	23'''-94'''	139'''-199'''		
Inter-H-L (h 5-CL 126)	229-219'	229"-219"		
Inter-H-H (h 11, h 14)	235-235"	238-238"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
306, 306"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

revefenacinum

revefenacin



1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]-*N*-methylbenzamido}ethyl)piperidin-4-yl *N*-([1,1'-biphenyl]-2-yl)carbamate

révéfénacine

N-([1,1'-biphenyl]-2-yl)carbamate de
1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]-*N*-méthylbenzamido}éthyl)pipéridin-4-yle

revefenacina

N-([1,1'-bifenil]-2-il)carbamato de
1-(2-{4-[(4-carbamoilpiperidin-1-il)metil]-*N*-metilbenzamida}etil)piperidin-4-il



rivabazumabum #
rivabazumab

immunoglobulin Fab' G1-kappa, anti-[*Pseudomonas aeruginosa* type III secretion system (TTSS) PcrV protein], humanized monoclonal antibody;
gamma1 heavy chain fragment VH-(CH1-hinge) (1-238) [humanized VH (*Homo sapiens*IGHV3-30*06 (92.90%) - (IGHD) -IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens*IGHG1*01 (CH1 (125-222), hinge C5>S (227) (223-237), CH2 (238)) (125-238)], noncovalently associated with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 C126>S (214') (108'-214')]

rivabazumab

immunoglobuline Fab' G1-kappa, anti-[protéine PcrV du système de sécrétion type III (TTSS) de *Pseudomonas aeruginosa*], anticorps monoclonal humanisé;
fragment VH-(CH1-charnière) de la chaîne lourde gamma1 (1-238) [VH humanisé (*Homo sapiens*IGHV3-30*06 (92.90%) - (IGHD) -IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens*IGHG1*01 (CH1 (125-222), charnière C5>S (227) (223-237), CH2 (238)) (125-238)], associé de manière non covalente avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 C126>S (214') (108'-214')]

rivabazumab

immunoglobulina Fab' G1-kappa, anti-[proteína PcrV del sistema de secreción tipo III (TTSS) de *Pseudomonas aeruginosa*], anticuerpo monoclonal humanizado;
fragmento VH-(CH1-bisagra) de la cadena pesada gamma1 (1-238) [VH humanizado (*Homo sapiens*IGHV3-30*06 (92.90%) - (IGHD) -IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens*IGHG1*01 (CH1 (125-222), bisagra C5>S (227) (223-237), CH2 (238)) (125-238)], asociado de modo no covalente con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 C126>S (214') (108'-214')]

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG VVQPRSLRL SCAASGFTFS NYPMHVVRQA PGKGLEWVAV 50
 ISYDGSERWY ADSVKGRTFI SRDNSKNTLY LEMNSLRPED TAVYYCARNR 100
 GDIIYDFTYA MDIWGQTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
 CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTPVSSSL 200
 GTQTYICNVN HKPSNTKVKD KVEPKSSDKT HTCPCCPA 238

Light chain / Chaîne légère / Cadena ligera
 DIQLTQSPST LSASVGDSTV ITCRASEGVD RFLAWYQQKP GRAPKLLIYD 50
 ASTLQSGVPS RFGSGSGTE FSLTISLQF DDVATYYCQH FWGTPYTFQG 100
 GTKLEIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLLNFFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYERHK VYACEVTHQG 200
 LSSPVTKSFN RGES 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 151-207
 Intra-L (C23-C104) 23'-88' 134'-194'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 None

ruclosporinum

ruclosporin


8-[(2*R*)-*N*-methyl-2-[2-(4-morpholinyl)ethoxy]glycine]cyclosporin A:
 cyclo[L-alanyl-D-alanyl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl-(3*R*,4*R*,6*E*)-3-hydroxy-*N*,4-dimethyl-L-2-aminooct-6-enoyl-L-2-aminobutanoyl-(2*R*)-*N*-methyl-2-[2-(morpholin-4-yl)ethoxy]glycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucyl]

ruclosporine

8-[(2*R*)-*N*-méthyl-2-[2-(4-morpholinyl)éthoxy]glycine]cyclosporine A:
 cyclo[L-alanyl-D-alanyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-valyl-(3*R*,4*R*,6*E*)-3-hydroxy-*N*,4-diméthyl-L-2-aminooct-6-énoyl-L-2-aminobutanoyl-(2*R*)-*N*-méthyl-2-[2-(morpholin-4-yl)éthoxy]glycyl-*N*-méthyl-L-leucyl-L-valyl-*N*-méthyl-L-leucyl]

ruclosporina

8-[(2*R*)-*N*-metil-2-[2-(4-morfolinil)etoxi]glicina]ciclosporina A:
 ciclo[L-alanil-D-alanil-*N*-metil-L-leucil-*N*-metil-L-leucil-*N*-metil-L-valil-(3*R*,4*R*,6*E*)-3-hidroxi-*N*,4-dimetil-L-2-aminooct-6-enoil-L-2-aminobutanóil-(2*R*)-*N*-metil-2-[2-(morfolin-4-il)etoxi]glicil-*N*-metil-L-leucil-L-valil-*N*-metil-L-leucil]

C₆₈H₁₂₂N₁₂O₁₄

ruzasvirum

ruzasvir


dimethyl *N,N'*-([*(6S)*-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6*H*-indolo[1,2-*c*][1,3]benzoxazine-3,10-diyl]bis{(1*H*-imidazole-4,2-diyl)[*(2S)*-pyrrolidine-2,1-diyl][*(2S)*-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate

ruzasvir

N,N'-([*(6S)*-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6*H*-indolo[1,2-*c*][1,3]benzoxazine-3,10-diyl]bis{(1*H*-imidazole-4,2-diyl)[*(2S)*-pyrrolidine-2,1-diyl][*(2S)*-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

ruzasvir

N,N'-([*(6S)*-6-(2-ciclopropil-1,3-tiazol-5-il)-1-fluoro-6*H*-indolo[1,2-*c*][1,3]benzoxazina-3,10-diil]bis{(1*H*-imidazol-4,2-diil)[*(2S)*-pirrolidina-2,1-diil][*(2S)*-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo

C₄₉H₅₅FN₁₀O₇S**satoreotidum trizoxetanum**

satoreotide trizoxetan


*S*²,*S*⁷-cyclo[*N*-{*(4RS)*-4-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]-4-carboxybutanoyl]-4-chloro-L-phenylalanyl-D-cysteinyl-4-[(*4S*)-2,6-dioxo-1,3-diazinane-4-carb-oxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-D-tyrosinamide]

satoréotide trizoxétan

*S*²,*S*⁷-cyclo[*N*-{*(4RS)*-4-[4,7-bis(carboxyméthyl)-1,4,7-triazonan-1-yl]-4-carboxybutanoyl]-4-chloro-L-phénylalanyl-D-cystéinyl-4-[(*4S*)-2,6-dioxo-1,3-diazinane-4-carb-oxamido]-L-phénylalanyl-4-(carbamoylamino)-D-phénylalanyl-L-lysyl-L-thréonyl-L-cystéinyl-D-tyrosinamide]

satoreotida trizoxetán

*S*²,*S*⁷-ciclo[*N*-{*(4RS)*-4-[4,7-bis(carboximetil)-1,4,7-triazonan-1-il]-4-carboxibutanoil]-4-cloro-L-fenilalanil-D-cisteinil-4-[(*4S*)-2,6-dioxo-1,3-diazinano-4-carboxamido]-L-fenilalanil-4-(carbamoilamino)-D-fenilalanil-L-lisil-L-treonil-L-cisteinil-D-tirosinamida]

$C_{73}H_{95}ClN_{18}O_{21}S_2$ **sevirteronelum**


sevirteronel

(1S)-1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(1*H*-1,2,3-triazole-4-yl)propan-1-ol

sevirteronel

(1S)-1-[6,7-bis(difluorométhoxy)naphtalén-2-yl]-2-méthyl-1-(1*H*-1,2,3-triazole-4-yl)propan-1-ol

sevirteronel

(1S)-1-[6,7-bis(difluorometoxi)naftalen-2-il]-2-metil-1-(1*H*-1,2,3-triazol-4-il)propan-1-ol $C_{18}H_{17}F_4N_3O_3$ **sitravatinibum**


sitravatinib

N-(3-fluoro-4-{{2-(5-{{(2-methoxyethyl)amino)methyl}pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yl}oxy}phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

sitravatinib

N-(3-fluoro-4-{{2-(5-{{(2-méthoxyéthyl)amino)méthyl}pyridin-2-yl)thiéno[3,2-*b*]pyridin-7-yl}oxy}phényl)-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

sitravatinib

N-(3-fluoro-4-{{2-(5-{{(2-metoxietil)amino}metil}piridin-2-il)tieno[3,2-*b*]piridin-7-il}oxi}fenil)-*N'*-(4-fluorofenil)ciclopropano-1,1-dicarboxamida $C_{33}H_{29}F_2N_5O_4S$ 

talinoxomerum
talinoxomer

poly[(prop-2-enoic acid)-co-{2-ethyl-2-[(prop-2-enoxy)methyl]propane-1,3-diyl di(prop-2-enoate)}]


talinoxomère

poly[(acide prop-2-énoïque)-co-{di(prop-2-énoate) de 2-éthyl-2-[(prop-2-énoxy)méthyl]propane-1,3-diyle}]

talinoxómero

poli[(ácido prop-2-enoico)-co-{di(prop-2-enoato de 2-etil-2-[(prop-2-enoiloxi)metil]propano-1,3-diilo)}]

$[[C_{15}H_{20}O_6]_x \cdot [C_3H_4O_2]_y]_n$ $y/x \approx 1000$



tamtuvetmabum #
tamtuvetmab

immunoglobulin G2_V-kappa-C-lambda, anti-[*Homo sapiens* CD52], caninized monoclonal antibody; gamma2 heavy chain chimeric (1-456) [chimeric VH (*Rattus norvegicus* IGHV7S6*01 (97.00%) -(IGHD) -*Canis lupus familiaris* IGHJ-E2RCC8) [8.10.12] (1-121) -*Canis lupus familiaris* IGHG2*02 (CH1 (122-219), hinge (220-237), CH2 (238-347), CH3 (348-454), CHS (455-456))(122-456)], (136-212')-disulfide with V-kappa-C-lambda light chain chimeric (1'-213') [*Rattus norvegicus* V-KAPPA (*Rattus norvegicus* IGKV22S7 (93.70%) -IGKJ1*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGLC1S1*01 V45.3>I (156) (108'-213')]; dimer (233-233":236-236")-bisdisulfide

tamtuvetmab

immunoglobuline G2_V-kappa-C-lambda, anti-[*Homo sapiens* CD52], anticorps monoclonal caninisé; chaîne lourde gamma2 chimérique (1-456) [VH chimérique (*Rattus norvegicus* IGHV7S6*01 (97.00%) -(IGHD) -*Canis lupus familiaris* IGHJ-E2RCC8) [8.10.12] (1-121) -*Canis lupus familiaris* IGHG2*02 (CH1 (122-219), charnière (220-237), CH2 (238-347), CH3 (348-454), CHS (455-456)) (122-456)], (136-212')-disulfure avec la chaîne légère V-kappa-C-lambda chimérique (1'-213') [*Rattus norvegicus* V-KAPPA (*Rattus norvegicus* IGKV22S7 (93.70%) -IGKJ1*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGLC1S1*01 V45.3>I (156) (108'-213')]; dimère (233-233":236-236")-bisdisulfure

tamtuvetmab

immunoglobulina G2_V-kappa-C-lambda, anti-[*Homo sapiens* CD52], anticuerpo monoclonal caninizado;

cadena pesada gamma2 quimérica (1-456) [VH quimérico (*Rattus norvegicus* IGHV7S6*01 (97.00%) -(IGHD) -*Canis lupus familiaris* IGHJ-E2RCC8) [8.10.12] (1-121) -*Canis lupus familiaris* IGHG2*02 (CH1 (122-219), bisagra (220-237), CH2 (238-347), CH3 (348-454), CHS (455-456))(122-456)], (136-212')-disulfuro con la cadena ligera V-kappa-C-lambda quimérica (1'-213') [*Rattus norvegicus* V-KAPPA (*Rattus norvegicus* IGKV22S7 (93.70%) -IGKJ1*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGLC1S1*01 V45.3>1 (156) (108'-213'')]; dímero (233-233'':236-236'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

EVKLLSEGGG LVQPGGSMRL SCAGSGTFT DFYMNWIRQP AGKAPEWLGF 50
IRDKAKGYTT EYNPSVRGRF TISRDNQNM LYLQMNTRLA EDTATYYCAR 100
EGHTAAPFDY WQOGLVTVS SASTTAPSVF PLAPSCGSTS GSTVALACLV 150
SGYFPEFVTV SWNSGSLTSG VHTFPSVLQS SGLYSLSSMV TVPSSRWPE 200
TFTCNVAHPA SKTKVDKVPV KRENGRVRP PDCPKCPAPE MLGGPSVFI 250
PPKPKDTLLI ARTPEVTCV VDLDPEDPEV QISWFVDGKQ MQTAKTQPRE 300
EQFNQTVRVV SVLPIGHQDW LKGGQFTCKV NNAKALPSPI RTISKARGQA 350
HQPSVYVLPF SREELSKNTV SLTCLIKDFP PPDIDVEWQS NGQQEPESKY 400
RTTFFQLDED GSYFLYSKLS VDKSRWQRGD TFCICAVMHEA LNHHTQKSL 450
SHSPGK 456

```

Light chain / Chaîne légère / Cadena ligera

```

DIKMTQSPSF LSASVGRVT LNCKASQID KYLNWYQQKL GESPKLLIYN 50
TNNLQGTGIP RFSGSGSGTD FTLTISSLQP EDVATYFCLQ HISRPRTFGG 100
GTHLTVLQGP KASPSVTLFP PSSEELGANK ATLVCLISDF YPSGVTVAWK 150
ADGSPITQGV ETTKPSKQSN NKYAASSYLS LTPDKWKSHS SFSCCLVTHEG 200
STVEKKVAPA ECS 213

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-98	148-204	268-328	374-434
	22"-98"	148"-204"	268"-328"	374"-434"
Intra-L (C23-C104)	23"-88"	135"-194"		
	23"-88"	135"-194"		
Inter-H-L (CH1 I1-CL I26)	136-212'	136"-212'"		
Inter-H-H (h 14, h 17)	233-233"	236-236"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
304, 304"

tarloxotinibi bromidum
tarloxotinib bromide

(2E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-N,N-dimethyl-N-[(1-methyl-4-nitro-1H-imidazol-5-yl)methyl]-4-oxobut-2-en-1-aminium bromide


bromure de tarloxotinib

bromure de (2E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-N,N-diméthyl-N-[(1-méthyl-4-nitro-1H-imidazol-5-yl)méthyl]-4-oxobut-2-én-1-aminium

bromuro de tarloxotinib

bromuro de (2E)-4-[[4-(3-bromo-4-cloroanilino)pirido[3,4-d]pirimidin-6-il]amino]-N,N-dimetil-N-[(1-metil-4-nitro-1H-imidazol-5-il)metil]-4-oxobut-2-en-1-aminium

C₂₄H₂₄Br₂ClN₉O₃




tenalisibum

tenalisib 3-(3-fluorophenyl)-2-[(1S)-1-[(7H-purin-6-yl)amino]propyl]-4H-1-benzopyran-4-one

ténalisib 3-(3-fluorophényl)-2-[(1S)-1-[(7H-purin-6-yl)amino]propyl]-4H-1-benzopyran-4-one

tenalisib 3-(3-fluorofenil)-2-[(1S)-1-[(7H-purin-6-il)amino]propil]-4H-1-benzopiran-4-ona

$C_{23}H_{18}FN_5O_2$


**tetrodotoxinum**

tetrodotoxin (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-amino-12-(hydroxymethyl)-1,4,4a,5,9,10-hexahydro-7H-5,9:7,10a-dimethano[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol

tétrodotoxine (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-amino-12-(hydroxyméthyl)-1,4,4a,5,9,10-hexahydro-7H-5,9:7,10a-diméthano[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol

tetrodotoxina (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-amino-12-(hidroximetil)-1,4,4a,5,9,10-hexahidro-7H-5,9:7,10a-dimetano[1,3]dioxocino[6,5-d]pirimidina-4,7,10,11,12-pentol



$C_{11}H_{17}N_3O_8$

**tezacaftorum**

tezacaftor 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide

tezacaftor 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide

tezacaftor 1-(2,2-difluoro-2H-1,3-benzodioxol-5-il)-N-{1-[(2R)-2,3-dihidroxiopropil]-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1H-indol-5-il}ciclopropano-1-carboxamida



timolumabum #
timolumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* AOC3 (amine oxidase copper containing 3 (EC 1.4.3.21), vascular adhesion protein 1, VAP1, VAP-1)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-444) [*Homo sapiens* VH (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimer (223-223":226-226")-bisdisulfide

timolumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* AOC3 (amine oxydase à cuivre 3 (EC 1.4.3.21), VAP-1, protéine d'adhérence vasculaire 1, VAP1, VAP-1)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-444) [*Homo sapiens* VH (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimère (223-223":226-226")-bisdisulfure

timolumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* AOC3 (amina oxidasa con cobre 3 (EC 1.4.3.21), proteína de adhesión vascular 1, VAP1, VAP-1)], *Homo sapiens* anticuerpomoclonal ;

cadena pesada gamma4 (1-444) [*Homo sapiens* VH (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimero (223-223":226-226")-bisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVESGGG VVQFGRSLRL SCAASGFTFF SYAMHWVRQT PGKLEWVAV 50
 IWFDSGSENY VDSVKGRFTI SRDASKNTLY LQMNTLRAED TAVYYCARD 100
 WSYFDYWGQG TLVTYSSAST KGPSVFFFLAP CSRSTSESTA ALGCLVKRDI 150
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSVSVTVPS SSLGKTYTIC 200
 NVDHKFSNTR VDKRVESEKYG PFCPCPAPPE FAGGFSVFLF PPKPKDTLMI 250
 SRTPEVTCVV VDVSEQDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300
 SVLTVLHQDW LNGKEYKCRV SNKGLPSSIE KTISKARGQP REPQVYTLFP 350
 SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TTPVLDSDGS 400
 FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKLSL SLGK 444

Light chain / Chaîne légère / Cadena ligera
 VIQLTQSPSS LSASVGDRTV ITCRASQGIS RALAWYQQKP GKGPKLLIYD 50
 ASSLESQVPS RFGSGSGGTD FTLTISLQP EDFATYYCQ FNSYPLTFGG 100
 GTRKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFEY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYKHKH VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 144-200 258-318 364-422
 22"-96" 144"-200" 258"-318" 364"-422"
 Intra-L (C23-C104) 23"-88" 134"-194"
 23"-88" 134"-194"
 Inter-H-L (CH1 10-CL 126) 131-214' 131"-214"
 Inter-H-H (h 8, h 11) 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 294, 294"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

vadadustatum
 vadadustat



[5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxamido]acetic acid

vadadustat

acide [5-(3-chlorophényl)-3-hydroxypyridine-2-carboxamido]acétique

vadadustat

ácido [5-(3-clorofenil)-3-hidroxipiridina-2-carboxamido]acético



vadastuximabum #
 vadastuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)], chimeric monoclonal antibody; gamma1 heavy chain (1-447) [*Mus musculus* VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2

	S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with kappa light chain (1'-214') [<i>Mus musculus</i> V-KAPPA (IGKV14-111*01 - IGKJ1*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 (108'-214')]; dimer (226-226":229-229")-bisdisulfide
vadastuximab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> CD33 (lectine 3 de type Ig-like liant l'acide sialique, SIGLEC3, SIGLEC-3, gp67, p67)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-447) [<i>Mus musculus</i> VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) - <i>Homo sapiens</i> IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Mus musculus</i> V-KAPPA (IGKV14-111*01 -IGKJ1*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 (108'-214')]; dimère (226-226":229-229")-bisdisulfure
vadastuximab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> CD33 (lectina de tipo inmunoglobulina 3 que se une al ácido siálico, SIGLEC3, SIGLEC-3, gp67, p67)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-447) [<i>Mus musculus</i> VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) - <i>Homo sapiens</i> IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Mus musculus</i> V-KAPPA (IGKV14-111*01 -IGKJ1*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 (108'-214')]; dímero (226-226":229-229")-bisdisulfuro
	<p>Heavy chain / Chaîne lourde / Cadena pesada</p> <p>QVQLVQSGAE VKKRPGASVKV SCKASGYTFT NYDINWVRQA PGQGLEWIGW 50 IYPGDGSKY NEKFRKAKATL TADTSTSTAY MELRLRSDD TAVYVCASGY 100 EDAMDYVGGQ TTVTIVSSAST KGPSVFFLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVVPS SSLGTQTYIC 200 NVNHKPSNTK VDKKVEPKSC DKHTCPCPCP APELLGGPCV FLFFPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKENWYVD GVEVHNARTK PREEQYNSTY 300 RVVSVLTVLH QDVLNGKEYK CKVSNKALPA PIKRTISKAK GPPEQVQYT 350 LPFSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPPVLDS 400 DGSFFLYSKL TVDKSRWQQG NWFVSCVMHE ALHNHYTQKS LSLSPGK 447</p> <p>Light chain / Chaîne légère / Cadena ligera</p> <p>DIQMTQSPSS LSASVGRVIT INCKASQDIN SYLSWFAQPK GKAPKTLIYR 50 ANRLVDGVPS RFGSGSGSDQ YTLTISLQOP EDFATYCYLQ YDFPPLTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYERKK VYACEVTHQG 200 LSSPVTKSFN RGEK 214</p> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <p>Intra-H (C23-C104) 22-96 144-200 261-321 367-425 22"-96" 144"-200" 261"-321" 367"-425"</p> <p>Intra-L (C23-C104) 23"-88" 134"-194" 23"-88" 134"-194"</p> <p>Inter-H-L (h 5-CL 126) 220-214' 220"-214" Inter-H-H (h 11, h 14) 226-226" 229-229"</p> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación</p> <p>H CH2N84.4: 297, 297"</p> <p>Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados</p> <p>Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales</p> <p>N-terminal pyroglutamylation (pE) by cyclisation of the N-terminal glutaminylation (Q) H VH Q1>pE: 1, 1"</p> <p>C-terminal trimming of the C-terminal lysine (K) H CHS K2: 447, 447"</p>

venglustatum


venglustat

(3*S*)-1-azabicyclo[2.2.2]octan-3-yl *N*-{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate

venglustat

N-{2-[2-(4-fluorophényl)-1,3-thiazol-4-yl]propan-2-yl}carbamate de (3*S*)-1-azabicyclo[2.2.2]octan-3-yle

venglustat

N-{2-[2-(4-fluorofenil)-1,3-tiazol-4-il]propan-2-il}carbamato de (3*S*)-1-azabicyclo[2.2.2]octan-3-iloC₂₀H₂₄FN₃O₂S**verdiperstatum**


verdiperstat

1-[2-(propan-2-yloxy)ethyl]-2-sulfanylidene-1,2,3,5-tetrahydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

verdiperstat

1-[2-(propan-2-yloxy)éthyl]-2-sulfanylidène-1,2,3,5-tétrahydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

verdiperstat

1-[2-(propan-2-iloxi)etil]-2-sulfanilideno-1,2,3,5-tetrahydro-4*H*-pirrolo[3,2-*d*]pirimidin-4-onaC₁₁H₁₅N₃O₂S**vobarilizumabum #**

vobarilizumab

immunoglobulin scFv VH-VH', anti-[*Homo sapiens* IL6R (interleukin 6 receptor, IL-6R, CD126)] and anti-[*Homo sapiens* ALB (albumin, human serum albumin, HSA)], humanized monoclonal antibody bispecific single chain; scFv (1-245) [humanized VH anti-IL6R (*Homo sapiens*IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-121) -9-mer tetraglycyl-seryl-triglycyl-seryl linker (122-130) -humanized VH' anti-ALB (*Homo sapiens* IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]

vobarilizumab

immunoglobuline scFv VH-VH', anti-[*Homo sapiens* IL6R (récepteur de l'interleukine 6, IL-6R, CD126)] et anti-[*Homo sapiens* ALB (albumine, sérum-albumine humaine, SAH)], anticorps monoclonal humanisé et bispécifique à chaîne unique;

scFv (1-245) [VH humanisé anti-IL6R (*Homo sapiens* IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-121) -9-mer tétraglycyl-séryl-triglycyl-séryl linker (122-130) -VH' humanisé anti-ALB (*Homo sapiens* IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]

vobarilizumab	<p>inmunoglobulina scFv VH-VH', anti-[<i>Homo sapiens</i> IL6R (receptor de la interleukina 6, IL-6R, CD126)] y anti-[<i>Homo sapiens</i> ALB (albúmina, albúmina sérica humana, ASH)], anticuerpo monoclonal humanizado biespecífico monocatenario;</p> <p>scFv (1-245) [VH humanizado anti-IL6R (<i>Homo sapiens</i> IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-121) -9-mer tetraglicil-seril-triglicil-seril vínculo (122-130) -VH' humanizado anti-ALB (<i>Homo sapiens</i> IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]</p> <pre> EVQLVESGGG LVQPGGSLRL SCAASGSVFK INVMAWYRQA PGKRELTVAG 50 IISGGSTSYA DSVKGRFTIS RDNARNTLYL QMNSLRPEDT AVYYCAFITT 100 ESDYDLGRRY WGQGTLLVTVS SGGGGSGGGS EVQLVESGGG LVQPGNSLRL 150 SCAASGFTFS SFGMSWVRQA PGKGLEWVSS ISGSGSDTLY ADSVKGRFTI 200 SRDNARNTLY LQMNSLRPED TAVYYCTIGG SLRSRSQGTLL VTVSS 245 </pre> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-chain C23 C104 22-95 152-226</p> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación None</p>
xentuzumabum # xentuzumab	<p>immunoglobulin G1-lambda1, anti-[<i>Homo sapiens</i> IGF1 (insulin-like growth factor 1, somatomedin C) and IGF2 (insulin-like growth factor 2, somatomedin A)], humanized monoclonal antibody;</p> <p>gamma1 heavy chain (1-447) [humanized VH (<i>Homo sapiens</i> IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfide with lambda1 light chain (1'-216') [humanized V-LAMBDA (<i>Homo sapiens</i> IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC2*01 A43>G (154) (111'-216')]; dimer (226-226'':229-229'')-bisdisulfide</p>
xentuzumab	<p>immunoglobuline G1-lambda1, anti-[<i>Homo sapiens</i> IGF1 (facteur de croissance 1 analogue à l'insuline, somatomédine C) et IGF2 (facteur de croissance 2 analogue à l'insuline, somatomédine A)], anticorps monoclonal humanisé;</p> <p>chaîne lourde gamma1 (1-447) [VH humanisé (<i>Homo sapiens</i> IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfure avec la chaîne légère lambda1 (1'-216') [V-LAMBDA humanisé (<i>Homo sapiens</i> IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC2*01 A43>G (154) (111'-216')]; dimère (226-226'':229-229'')-bisdisulfure</p>
xentuzumab	<p>inmunoglobulina G1-lambda1, anti-[<i>Homo sapiens</i> IGF1 (factor de crecimiento 1 análogo a la insulina, somatomedina C) y IGF2 (factor de crecimiento 2 análogo a la insulina, somatomedina A)], anticuerpo monoclonal humanizado;</p>

cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215)-disulfuro con la cadena ligera lambda1 (1'-216') [V-LAMBDA humanizado (*Homo sapiens* IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC2*01 A43>G (154) (111'-216')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVELVESGGG LVQPGGSLRL SCAASGFTFT SYWMSWVRQA PGKGLLELVSS 50
ITSYGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYICARM 100
YTHFDSWGQG TLVTVSSAST KGPSVFLPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVP SSSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKHTTCPCPC APELLGGPSV FLFPPKPKDT 250
LMSRTPPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTSKAK GQPREPQVYV 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPPVLD 400
DGSFFLYSKL TVDKSRWQQG NVFSCVMHE ALHNHYTQKS LSLSPGK 447
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQPPSV SGAPGQRVTI SCSGSSSNIG SNSVSWYQQL PGTAPKLLIY 50
DNSKRPSGVP DRFSGSKSGT SASLAITGLQ SEDEADYCC SRDTYGYIYW 100
FGGGTKLTVL GQPKAAPSVT LFPSSSEELQ ANKATLVCLI SDFYPGAQVTV 150
AWKGDSSPVK AGVETTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS 216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	261-321	367-425
	22"-96"	144"-200"	261"-321"	367"-425"
Intra-L (C23-C104)	22'-89"	138"-197"		
	22'''-89'''	138'''-197'''		
Inter-H-L (h 5-CL 126)	220-215'	220"-215"		
Inter-H-H (h 11, h 14)	226-226'	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

297, 297"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

zoliflodacinum

zoliflodacin

(2'*R*,4'*S*,4'*aS*)-11'-fluoro-2',4'-dimethyl-8'-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'-tetrahydro-6'*H*-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3-a][1,2]oxaz-olo[4,5-g]quinoline]-2,4,6-trione


zoliflodacine

(2'*R*,4'*S*,4'*aS*)-11'-fluoro-2',4'-diméthyl-8'-[(4*S*)-4-méthyl-2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'-tétrahydro-6'*H*-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3-a][1,2]oxaz-olo[4,5-g]quinoline]-2,4,6-trione

zoliflodacina

(2'*R*,4'*S*,4'*aS*)-11'-fluoro-2',4'-dimetil-8'-[(4*S*)-4-metil-2-oxo-1,3-oxazolidin-3-il]-1',2',4',4'-tetrahydro-6'*H*-spiro[1,3-diazinano-5,5'-[1,4]oxazino[4,3-a][1,2]oxaz-olo[4,5-g]quinolina]-2,4,6-triona

C₂₂H₂₂FN₅O₇



**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 59
Dénominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 58 **lonaprisanum**
lonaprisan
lonaprisan
lonaprisán

replace the chemical name by the following one
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-4,9-dien-3-one

11β-(4-acétylphényl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-prégna-4,9-dién-3-one

11β-(4-acetylfenil)-20,20,21,21,21-pentafluoro-17-hidroxi-19-nor-17α-pregna-4,9-dien-3-ona

Recommended International Nonproprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)

p. 58 **daclatasvirum**
daclatasvir
daclatasvir
daclatasvir

replace the chemical name by the following one
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

dimethyl *N,N'*-([1,1'-biphenyl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate
N,N'-([1,1'-biphényl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

N,N'-([1,1'-bifenil]-4,4'-diilbis{1*H*-imidazol-5,2-diil-[(2*S*)-pirrolidina-2,1-diil][(2*S*)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo

Recommended International Nonproprietary Names (Rec. INN): List 71

Dénominations communes internationales recommandées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No. 1, 2014)

p. 90 **idarucizumabum**

- 91 idarucizumab
 idarucizumab
 idarucizumab

replace the description by the following one
remplacer la description par la suivante
sustitúyase la descripción por la siguiente

immunoglobulin Fab G1-kappa, anti-[dabigatran], humanized monoclonal antibody;
 VH-(CH1-hinge) gamma1 heavy chain (1-225) [humanized VH (*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) - *Homo sapiens* IGHG1*01 (CH1 (123-220), hinge 1-5 (221-225)) (123-225)], (225-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

immunoglobuline Fab G1-kappa, anti-[dabigatran], anticorps monoclonal humanisé;
 chaîne lourde VH-(CH1-charnière) gamma1 (1-225) [VH humanisé(*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16](1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), charnière 1-5 (221-225)) (123-225)], (225-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

immunoglobulina Fab G1-kappa, anti-[dabigatrán], anticuerpo monoclonal humanizado;
 cadena pesada VH-(CH1-bisagra) gamma1 (1-225) [VH humanizado (*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), bisagra 1-5 (221-225)) (123-225)], (225-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.